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2.1. Wnt/β-catenin signaling in the intestinal epithelium 
2.1.1. The Wnt/β-catenin signaling pathway 
In multicellular organisms the so called canonical Wnt or Wnt/β-catenin signaling 
pathway is an essential regulator of embryonic development such as body axis 
patterning and tissue morphogenesis and is required for tissue homeostasis and 
stem cell proliferation in the adult. In cooperation with other signaling cascades it 
controls a complex interplay between processes involved in cell proliferation, 
migration, differentiation, adhesion and death. Therefore, a deregulation of the 
Wnt/β-catenin signaling pathway is a frequent event occurring in human cancers 
and other degenerative diseases (1-5). 
β-catenin represents the central element of this signal transduction pathway and 
was initially described as a component of the cadherin-catenin cell adhesion 
complex at adherence junctions (6). 
In the absence of Wnt molecules, which are secreted glycoproteins, β-catenin is 
phosphorylated by a multi protein complex consisting of CKI (casein kinase I), 
GSK3 (glycogen synthase kinase 3) and the scaffolding proteins APC 
(adenomatous polyposis coli) and Axin/Axin2 (7-10). This phosphorylation at 
specific residues of the N-terminus of β-catenin (Ser 33, 37, 41, 45) leads to 
subsequent ubiquitination and proteosomal degradation of the protein. Activation 
of the Wnt/β-catenin signaling pathway occurs when Wnt ligands bind to the 
transmembrane Frizzled/LRP (low density lipoprotein receptor-related protein) 
receptor complex (11-14). It has been suggested that recruitment of Axin to LRP 
on the membrane results in disruption of the destruction complex (15), leading to 
stabilization and nuclear translocation of β-catenin. The resulting accumulation of 
β-catenin in the nucleus increases the activation of target genes via interaction 
with members of the TCF/LEF (T cell factor/lymphoid enhancer factor) family of 
transcription factors. TCF/LEFs target β-catenin to specific DNA elements found 
in promoters and enhancers of target genes (16-18) (Figure 1). In the absence of 
 




nuclear β-catenin, TCF forms a complex with Groucho and histone deacetylases 




Figure 1: The Wnt/β-catenin signaling pathway. In the absence of extracellular Wnt molecules, 
β-catenin becomes phosphorylated by the destruction complex consisting of Conduction, CKI 
(casein kinase I), GSK3 (glycogen synthase kinase 3), APC (adenomatous polyposis coli) and 
Axin. This marks β-catenin for proteasomal degradation. Upon Binding of Wnt ligands to the 
transmembrane Frizzled/LRP receptor complex β-catenin becomes stabilized and translocates into 
the nucleus where it binds to DNA-bound transcriptional factors of the LEF/TCF family to activate 
the transcription of target genes (adapted from (21). 
 
The transcriptional function of β-catenin is further modulated by several nuclear 
factors, e.g. the histone acetylase CBP/p300 (CREB [cAMP-responsive-element-
binding protein] binding protein) and the SWI/SNF (switching-defective and 
sucrose nonfermenting) chromatin remodeling complex component BRG1 (22-
24).  
Moreover the novel Legless/BCL9 and Pygopus (Pygo) proteins emerged as 
nuclear co-factors in Wnt/β-catenin signaling (25-28). Based on Drosophila 
studies it has been proposed that Legless/BCL9 proteins act as adapter to 
 




physically link Pygopus to β-catenin. Thus, the function of Pygopus appears to 
induce nuclear localization of the β-catenin/BCL9 complex (26;29;30) (Figure 1). 
2.1.2. The role of Wnt/β-catenin signaling in intestinal development and 
homeostasis 
Wnt/β-catenin signaling is required for gut tube formation and involved in the 
regulation of the development of nearly all endoderm-derived organs including 
the gastrointestinal tract. Canonical Wnt molecules mediate both differentiation 
and proliferation at different steps during gut organogenesis (31). In ascidians and 
mice the Wnt/β-catenin signaling pathway has been shown to be essential for 
endoderm formation (32;33) but to date the exact underlying mechanisms 
remained unclear. However mutations in components of this signal transduction 
pathway affect gut development at various stages (34-37). 
In mice the embryonic gut development is initiated around embryonic day E7.5 
and E9.5 simultaneously in the anterior and posterior part of the developing 
embryo. At this time point the early intestine is composed of the endoderm-
derived epithelium and the surrounding outer layer of splanchnic mesoderm. The 
latter differentiates to a smooth muscle layer, whereas the luminal epithelium is 
highly proliferating and undergoes regional specification along the anterior–
posterior (A-P) axis around E14.5 (38). This process is completed around E18.5 
when the epithelium of the small intestine has formed numerous characteristic 
finger-like projections called villi that point toward the lumen. The resulting 
dramatically increased surface area of the small intestine allows the efficient 
absorption of nutrients. In contrast, in the colon there are no villi formed but a flat 
surface epithelium is mainly responsible for the compaction of stool (Figure 2). 
The villi of the small intestine mainly consist of differentiated cells. The 
undifferentiated proliferating cells are located in the intervillous region. By deep 
invaginations into the submucosa they develop to the crypts of Lieberkühn in the 
first weeks after birth (Figure 2) (39;40).  
 





Figure 2: Developmental stages of the intestinal epithelium (41). The embryonic gut develops 
from a multilayered stratified epithelium that forms villi (small intestine) or a unistratified 
epithelium (colon) by mesodermal outgrowth. The intervillous regions harbor the proliferating 
cells and develop to the small intestinal crypts after birth. The colonic crypt compartment rises 
from the flat crypt like structures that invaginate deeper into the mesodermal layer. 
 
The adult intestinal stem cells (ISCs) are located at the base of these crypts. They 
continuously produce the so called transit amplifying (TA) crypt progenitors, 
which divide every 12–16 hours and reside for up to six rounds of cell divisions 
within the crypts (42). During this time the progenitor cells migrate upward the 
villi and differentiate to the mature cell types of the intestinal epithelium, the 
absorptive enterocytes, the mucous secreting goblet cells and the hormone 
producing enteroendocrine cells. Upon reaching the tips of the villi the 
differentiated cells undergo apoptosis and are shed into the lumen. The Paneth 
cells are an exception since they are generated from a progenitor migrating 
downward toward the crypt base. They secrete peptides and enzymes responsible 
for microbial defense (Figure 3).  
 




Wnt/β-catenin signaling in the intestinal epithelium is active in a gradient with the 
highest activity in the proliferating crypt compartment where epithelial cells show 
high expression of several pathway components like Wnt-3, Wnt-6, Wnt 9b, 
Frizzled 4, Frizzled 6, Frizzled 7 and Lrp5 sFrp5 (43). Moreover, they express 
several Wnt/β-catenin target genes like c-myc, EphB2 and CDCA7. In contrast, 
genes suppressed by Wnt/β-catenin signaling, such as p21 and Smad2, are 
expressed at the top of the crypts (44;45). Moreover intestinal progenitors located 
at the bottom of the crypts show an accumulation of nuclear β-catenin that 
decreases to the interface of the villus. Upon the villus axis only membrane 
associated β-catenin persists (45). 
In agreement with this, Wnt/β-catenin signaling in the intestinal epithelium is 
especially essential for the maintenance of homeostasis. This has been shown in 
several studies where inhibition of the pathway or deletion of pathway 
components led to loss of the proliferative compartment (46-53) and mutational 
activation resulted in hyperproliferation and adenoma development (50-52;54-57).  
Moreover Wnt/β-catenin signaling functions in differentiation of the secretory cell 
lineages, in positioning and maturation of Paneth cells via regulation of the 
EphB/ephrin-B system as well as in the separation of proliferating and 
differentiated cells (58-60). 
 
2.1.3. Wnt/β-catenin signaling in intestinal stem cells  
The ISCs ensure the permanent cell replacement in the intestinal epithelium, 
which has a remarkably capacity to self-renew with a turn over time of three to 
five days in mouse. Stem cells are mainly defined by two properties: (1) the 
capability to generate all differentiated cell types of the respective tissue 
(multipotency) and (2) the capacity to maintain over long periods of time 
(longevity) (61). Moreover stem cells are believed to be quiescent. They divide 
infrequently and produce one rapidly cycling daughter cell and one new stem cell 
(asymmetric cell division).  
Currently two models of the exact identity of the intestinal stem cells exist, the 
“+4 position” model and the “stem cell zone” model (Figure 3). According to 
 




label-retaining experiments the ISCs are supposed to reside at position +4 relative 
to the crypt bottom and directly above the Paneth cells (62). One molecular 
marker gene that is specifically expressed in these cells is the Polycomb group 
gene Bmi1. Lineage tracing experiments have shown that Bmi1 expressing cells 
are able to proliferate, expand, self-renew and produce all the differentiated cell 
types of the small intestinal epithelium (63). 
The “stem cell zone” model proposes small, undifferentiated, cycling cells, the so 
called CBC (crypt base columnar) cells, located at the crypt bottom between the 
Paneth cells, as the ISCs (64-67). The Wnt/β-catenin target gene Lgr5, a leucine 
rich orphan G protein coupled receptor, specifically marks CBC cells at the base 
of small intestinal crypts as well as similar cells in colonic crypts and has been 
shown to display longevity and multipotency  (68).  
Recently the functional differences of Lgr5 positive CBC and Bmi1 positive +4 
cells have been analyzed in more detail and propose distinct ISC populations that 
facilitate homeostatic and injury-induced regeneration (69). While Lgr5 marks 
actively cycling stem cells (~ every 24 hours) (68), Bmi1 positive cells are 
supposed to be quiescent and contribute less to homeostatic regeneration. In 
contrast, after irradiation Bmi1 positive ISCs are induced and capable to 
repopulate the intestinal epithelium, whereas Lgr5 positive ISCs disappear (69). 
The effect of Wnt/β-catenin signaling on intestinal homeostasis is mediated by the 
regulation of the ISC pools (58;70). As mentioned above tissue self-renewal is 
mediated by stem cells and Wnt/β-catenin pathway inactivation in the intestine 
e.g. by conditional deletion of β-catenin completely blocks intestinal homeostasis 
(50). Furthermore, Apc deficient intestinal epithelial cells exhibit increased 
Wnt/β-catenin signaling and resemble a “crypt progenitor-like” phenotype due to 
disturbed differentiation, migration and apoptosis accompanied by dramatically 
increased proliferation (55).  
 
 





Figure 3: Proposed models for the position of the intestinal stem cells (ISCs) (71). The stem 
cells of the intestinal epithelium are located at the bottom of the crypts. The “+4 position” model 
places the ISCs directly above the Paneth cells whereas the “stem cell zone” model proposes the 
crypt base columnar cells, which are intermingled between the Paneth cells, as the ISCs. Both give 
rise to the highly proliferating transit-amplifying progenitor cells that differentiate to either 
absorptive enterocytes, mucous secreting goblet cells, hormone producing enteroendocrine cells or 
antimicrobial Paneth cells. 
 
2.1.4. Wnt/β-catenin signaling in intestinal tumorigenesis 
Enhanced Wnt/β-catenin signaling is not only common to the normal intestinal 
stem cell compartment but also found in colorectal cancer.  
The high tissue turnover rate of the intestinal epithelium entails an increased risk 
of developing cancer. According to the multistep model of intestinal 
carcinogenesis deregulations in the Wnt/β-catenin signaling pathway are already 
found in the very early stages of colorectal neoplasia (72). Loss- and gain-of-
function mutations of pathway components, most commonly in the APC tumor 
suppressor gene or in β-catenin itself, are supposed to be the initial event and 
 




occur in ~ 90 % of colorectal cancers (72-78). These mutations lead to 
constitutive activation of Wnt/β-catenin signaling, and the resulting accumulation 
of β-catenin in the nucleus increases the activation of target genes (79). This is 
contradictory to the results of immunohistochemical and Wnt reporter analysis, 
which revealed that not all colorectal cancers display nuclear β-catenin and show 
rather heterogeneous levels of Wnt signaling (80-82). The so called β-catenin 
paradoxon can be well explained by the cancer stem cell hypothesis that only a 
subset of tumor cells with stem-like properties, the cancer stem cells (CSCs) or 
tumor-initiating cells, are featured with tumorigenic potential (83). According to 
this hypothesis, mutations either convert normal stem cells into CSCs or they 
cause redifferentiation of cells toward a stem cell-like behavior (84).  
This is supported by the findings that hyperactivation of  Wnt/β-catenin signaling 
in normal Bmi1 or Lgr5 positive stem cells but not in non-stem cell populations is 
enough to drive tumor formation in the mouse small intestine (63;85). 
Familial adenomatous polyposis (FAP) is an autosomal dominant disease caused 
by germline Apc mutations and characterized by the formation of 100’s to 1000’s 
of colonic polyps (86-88). The first mouse model that resembles FAP was the 
ApcMin mouse (multiple intestinal neoplasia), which was found to carry a 
truncation mutation at codon 850 of the Apc gene and developed up to 100 polyps 
in the small intestine in addition to colon tumors (89;90). In addition, the majority 
of sporadic colonic adenomas and carcinomas in humans (~ 85 %) carry somatic 
mutations in the APC gene (72;74;91;92). The majority of somatic Apc mutations 
occur in the so called mutation cluster region located between codons 1250 and 
1514 and result in retained expression of an N-terminal fragment of the APC 
protein (91;93;94). Mutations in this region affect the ability of APC to bind and 
consequently degrade β-catenin. In general, the degree of the deletion or mutation 
within the Apc gene correlates with the level of Wnt/β-catenin activation in the 
tumor cell and influences the number and distribution of intestinal polyps (95;96). 
Interestingly, the location of the mutation is also associated with tumor location 
within the gastrointestinal tract (97-99).  
However, mutations in Wnt/β-catenin pathway components alone are not 
sufficient to drive the progression of adenomas to carcinomas and metastasis. 
Rather, additional mutations in other signaling pathways, such as activating 
 




mutations in Ras and loss-of-function mutations in p53, are also required 
(100;101).  
 
2.2. The role of Pygo2 in development and disease 
2.2.1. Pygopus proteins are nuclear co-factors of Wnt/β-catenin signaling 
Pygopus has been initially identified in Drosophila as absolutely required for β-
catenin mediated Wg/Wnt signaling (Wg is the fly Wnt counterpart), since 
embryonic and adult phenotypes of Pygo deficient flies were consistent with loss 
of Wg/Wnt signaling (segment polarity phenotype). Moreover expression of 
Wg/Wnt target genes was found to be reduced or completely abolished in 
Drosophila embryos containing dPygo null alleles (25-28). Similar results were 
obtained from studies in Xenopus where xPygo depletion lead to embryonic 
defects, particularly in embryonic brain patterning, and a reduction in Wnt target 
gene expression (25;102). In addition to their transcriptional co-activator function 
Pygo proteins are supposed to be required for nuclear retention of β-catenin. They 
have two distinct conserved domains, an N-terminal homology domain (NHD) 
and a C-terminal PHD (plant homeo domain) zinc finger motif (25-28). Several 
studies provided evidence that the NHD domain of Pygo has transactivation 
capability (29;103;104), whereas the PHD finger has been shown to interact with 
legless/BCL9, which in turn binds to the N-terminal domain of β-catenin. Thus, 
the function of legless/BCL9 appeared to act as an adapter protein between β-
catenin and Pygo (26;29;105). Legless/BCL9 was just like Pygopus identified as 
essential co-factor of Wg/Wnt signaling during Drosophila development (26).  
Plant homeo domains are implicated in chromatin remodeling and bind to 
methylated residues on lysine 4 of histone H3 (H3K4me), which is strongly 
associated with active transcription (106-108). Indeed, there is experimental 
evidence that Pygo proteins exhibit H3K4me3-decoding function, since they were 
shown to interact in vivo with trimethylated (me3) K4 residues of histone H3 and 
this interaction was critical for Drosophila development (109) and mammary 
progenitor cell expansion (110). Furthermore, an increasing number of studies 
 




demonstrated that these proteins are involved in promoting trimethylation of 
H3K4 and acetylation (Ac) of H3K9/K14 (110-113). The transcriptional activity 
of human Pygo2 has been shown to be increased by complex formation with CBP, 
a histone acetyltransferase (HAT), in HEK293 and SW480 cells (111). CBP was 
required for histone acetylation at Wg target genes upon Wg stimulation in 
Drosophila (114) and was found to be present at the promoters of mammalian 
Wnt/β-catenin target genes in a complex with β-catenin/TCF (22-24;115). In 
human breast cancer cells Pygo2 facilitated β-catenin-HMT/HAT interaction and 
associated itself with the MLL2 histone methyltransferase (HMT) complex and 
the GCN5 histone acetyltransferase. This interaction was important for 
HMT/HAT binding to the Wnt/β-catenin target genes c-myc and Lef1 (113). 
Thus, in addition to their function as transcriptional co-factors Pygo proteins are 
implicated in chromatin remodeling and seem to act as scaffold proteins that bring 





Figure 4: Schematic illustration summarizing the current findings about the multiple 
interactions mediated by Pygopus proteins. Interaction of Pygo and β-catenin occurs via 
Lgs/BCL9 which bind by their homology domain 1 (HD1) to the PHD (plant homeo domain) 
finger in the C terminus of Pygo and by their homology domain 2 (HD2) to the first two Armadillo 
repeats of β-catenin. The PHD finger further binds to Histone 3 trimethylated at lysine 4 (K4). The 
NHD (N-terminal homology domain) of Pygo associates with histone methyltransferases (HMT) 








2.2.2. Mammalian Pygopus proteins 
In contrast to Drosophila ablation of Pygo genes in mice did not always 
phenocopy mutants with loss of Wnt signaling and it seems that the two 
mammalian homologues Pygo1 and Pygo2 exhibit more context dependent 
functions (25;26;28;117;118). Expression analysis in mice revealed a broad 
expression spectrum of mPygo2 during embryonic development and in adult 
tissues (brain, heart, kidney, liver, lung, skin, small intestine, spleen, stomach, 
testis tissue, and thymus), whereas mPygo1 was only expressed in heart tissue 
(117).  
Consistent with this mPygo1 knock-out mice were viable and fertile with no 
obvious developmental defects whereas ablation of mPygo2 was perinatal lethal 
and caused severe developmental defects such as exencephaly, abnormal eye and 
lung development, reduced hair follicle density, hypoplasia of kidney and 
pancreas, impaired mammary gland morphogenesis and spermiogenesis arrest 
with resulting infertility (110;112;118-121).  
Interestingly, the reported phenotypes were less severe than those observed in β-
catenin knock-out mice (122;123) and Wnt reporter activity in most mPygo2-
deficient tissues was reduced but not completely abolished (118). This indicates 
that Pygo2 functions more as a modulator of canonical Wnt/β-catenin signaling in 
mammalian tissues. Moreover, it has been suggested that Pygo2 might have 
Wnt/β-catenin independent functions since not all of the described phenotypes 
were consistent with loss of Wnt signaling (112;120).  
In the developing kidney Pygo2 was required for the expression of a canonical 
Wnt reporter and implicated in Wnt/β-catenin signaling in the branching 
morphogenesis of the ureteric bud. Loss of Pygo2 resulted in reduced kidney size, 
dilated tips and a decrease in ureteric tip density. However, although Wnt/β-
catenin signaling is important for nephrogenesis, nephron formation was 
unaffected in Pygo2 mutant kidneys (119). Similarly, the dependency of 
mesenchymal canonical Wnt signaling on Pygo2 during pancreas development 
has been established. Here a decreased proliferation of undifferentiated 
progenitors as well as a reduction of the endocrine progenitor cell population was 
observed after E12.5 in Pygo2 mutant mice. This resulted in pancreas hypoplasia 
 




and defective endocrine cell differentiation (121). Lung morphogenesis, which 
has been shown to require β-catenin (124), was also impaired in Pygo2 deficient 
embryos (118) and closely resembled the effect of inducing Dkk1 (a Wnt 
inhibitor) expression in lung epithelia of developing mice (125). 
In contrast, Pygo2 and Wnt/β-catenin have distinct functions during lens 
development suggesting that the role of Pygo2 in the ocular mesenchyme and 
presumptive lens ectoderm is independent of canonical Wnt signaling (120). A 
Wnt/β-catenin independent involvement of Pygo2 has also been reported during 
spermatogenesis. Expression of hypomorphic alleles of Pygo2 in testis led to 
infertility and drastic spermiogenic defects (112). 
Such context dependent functions in canonical Wnt signaling seem to be a 
common feature of transcriptional co-activators of β-catenin, as they were also 
described for the mammalian BCL9 proteins.  
Importantly, although expressed in the murine intestine both the BCL9 and Pygo 
proteins, are obviously dispensable for normal intestinal homeostasis 
(118;126;127), a process that is tightly controlled by the Wnt/β-catenin signaling 
pathway (see 2.1.2). Whereas Pygo2 and BCL9 were ubiquitously expressed in all 
intestinal cells, expression of BCL9-2 was restricted to the nuclei of the epithelial 
cells in the villi. Pygo1 expression was completely absent in the intestine (126). 
Anyhow, neither the inducible knock-out of BCL9/BCL9-2 nor the 
overexpression of BCL9-2 in the intestinal epithelium did reveal any 
abnormalities (126;127) and the embryonic intestine of Pygo2 deficient mice was 
indistinguishable from wildtype mice (118). However, BCL9/BCL9-2 double 
mutant intestines displayed reduced expression of several intestinal stem cell 
markers, including Lgr5, accompanied by an impaired regenerative capacity after 
colitis induction with dextran sulfate sodium. Thus, BCL9/BCL9-2 apparently 
control a subset of canonical Wnt regulated genes implicated in stem cell 
maintenance (127). Due to the lack of single knock-out studies it remains unclear 
if the resulting phenotypes arose from loss of both BCL9 proteins or if the 
mutation of one gene was sufficient.  
Since the co-activator function of BCL9 proteins in vertebrate Wnt/β-catenin 
signaling has been shown to depend only partially on Pygo (128-130), the 
contribution of Pygo proteins in these processes will need further investigations.  
 




A detailed analysis of the role of Pygo2 in Wnt/β-catenin signaling in the 
intestinal epithelium is lacking so far, but recently Pygo2 has been implicated in 
stem cell homeostasis in another epithelial system, the mammary gland. Besides 
its role in mammary morphogenesis, Pygo2 was required for mammary progenitor 
cell proliferation. Thereby it regulated cell cycle and Wnt/β-catenin target gene 
expression and facilitated trimethylation of H3K4 at specific Wnt target loci and 
also in bulk chromatin, indicating that Pygo2 may contribute to an active 
chromatin status (110).  
However, if the proteins of the BCL9 and Pygopus family cooperate in the 
regulation of stem cell maintenance or just have independent functions as nuclear 
co-factors of β-catenin in epithelial tissues merits further investigation. Certainly, 
they contribute to, rather than being essential for β-catenin mediated transcription 
in mammalian tissues. 
 
2.2.3. Implications for a role of Pygo2 in cancer 
Several studies have implicated that Pygo2 may be involved in neoplastic 
transformation of multiple tissues. Thus, Pygo2 was found to be overexpressed in 
epithelial ovarian cancer (131), breast cancer (132) and glioma (133;134) and has 
been shown to be required for the growth of these tumors. In addition, loss of 
Pygo2 was able to rescue mammary outgrowth induced by stabilized β-catenin 
(110). 
Moreover, several findings indicate a role of Pygo2 in Wnt/β-catenin signaling in 
intestinal tumorigenesis. High levels of Pygo2 protein were found in established 
colon cancer cell lines (126) and siRNA mediated knock-down of Pygo2 in 
SW480 and HCT116 cells resulted in the inhibition of TCF/LEF-mediated 
transcriptional activation of reporter genes (28;126). Furthermore, a co-
transfection of dPygo together with Legless increased the nuclear levels of 
endogenous β-catenin as well as the TCF/β-catenin-mediated transcription in Apc 
deficient colon cancer cells, indicating that they cooperate in stimulating 
canonical Wnt signaling in these cells (30). Recently, we have extensively 
characterized the regulation of endogenous Wnt/β-catenin target genes by the 
BCL9/BCL9-2 and Pygo2 proteins in SW480 colon cancer cells and found that 
 





they co-regulated only a subset of canonical Wnt target genes. Their knock-down 
down-regulated Axin2, c-myc, EphB2 and Tcf1 as well as the BMP signaling 
components BMP4 and Bambi, whereas the expression of other Wnt/β-catenin 
target genes, such as cyclin D1, Lef1 or Msx2, was controlled by β-catenin alone 
(126). In addition, we demonstrated that both the BCL9s and Pygo2 specifically 
regulated the expression of the EphB3/B4 receptors and the EphrinB1/B2/B3 
ligands, which are implicated in intestinal cancer (135) independently of β-catenin 
(126). 
We further provided in vivo evidence for a role of Pygo2 and BCL9-2 in intestinal 
tumorigenesis, since both were overexpressed in intestinal adenomas of mice 
carrying a mutant Apc gene as well as in human colon cancer (126). However, 
ablation of BCL9-2 in conditional BCL9/BCL9-2 knock-out mice did not prevent 
or reduce chemically induced colon carcinogenesis (127), whereas its transgenic 
overexpression induced intestinal tumorigenesis and enhanced adenoma 
development in ApcMin/+ mice (126).  BCL9-2 is therefore supposed to promote 
early phases of intestinal tumor progression. 
Although this variety of data clearly implicates Pygo2 in cancer development, the 
mechanisms of its deregulation are still not known. According to our own results, 
Pygo2 itself is no target of Wnt/β-catenin signaling in colon cancer cells, 
indicating that the upregulation of Pygo2 in intestinal tumors is independent of 
Wnt/β-catenin signaling (126). However, one possible mechanism responsible for 
overexpression of Pygo2 in breast cancer was published by Andrews et al.. In 
MCF7 breast cancer cells they identified two overlapping tandem Ets transcription 
factor-binding sites in the hPygo2 promoter and provided evidence that the E74-
like factor-1 (Elf-1) is involved in transcriptional activation of hPygo2 (136). 
Moreover, the data from Gu et al. that Pygo2 associated with histone 
methyltransferase in bulk chromatin and not only at Wnt target genes (110) 
strongly implicates that Pygo2 is regulated by other pathways. 




3. Aims of the study 
 
The Wnt/β-catenin signaling pathway has a key role in the intestinal epithelium. 
However the implication of its nuclear cofactor Pygo2 in the regulation of 
intestinal development, tissue homeostasis and tumor formation remained unclear 
so far. We therefore used conditional knock-out strategy to specifically delete 
Pygo2 in the intestine in a temporally and spatially controlled manner. The loss of 
Pygo2 was induced by Cre recombinase under control of the Villin-promoter and 
the mice were analyzed at defined time points consistent with specific states of 
organ development and tumorigenesis.  
Embryonic gut development after loss of Pygo2 in the intestinal epithelium was 
histological examined shortly before birth. Furthermore, the homeostatic self-
renewal of the adult intestine was studied by analyzing the proliferation, 
differentiation, migration and Wnt/β-catenin signaling activity.  
In order to assess the role of Pygo2 in intestinal tumorigenesis two additional 
mouse models were established in this work that allowed us to specifically delete 
Pygo2 in the context of activated Wnt/β-catenin signaling. Tumor development 
after loss of Pygo2 in β-catenin and Apc mutant mice was macroscopically and 
microscopically analyzed. Moreover, tumors from both mouse models were 
extensively characterized by immunohistochemistry and quantitative real-time 
PCRs for the expression of Wnt signaling components and target genes, intestinal 
stem cell markers and activation of other signaling pathways. 
 






4.1. General material 
Cover Slips Thermo Scientific 
Cryovials Nunc 
Culture plates (100 mm ∅) Nunc 
Filters for solutions (0.2 μm and 0.45 μm) Sartorius 
Flasks for cell culture (75 cm2) Sarstedt 
Gloves (nitrile, latex) Sempermed 
Hybond-P PVDF membrane GE Healthcare 
Hypodermic needle (23 G) BBraun 
Pasteur pipettes Peske OHG 
Petri dishes Falcon 
Pipettes (2, 5, 10 and 25 ml) Eppendorf 
Pipette tips (10, 200 and 1000 μl) MbP 
Pipette tips (10, 200 and 1000 μl with a filter) Biozym 
Plates for cell culture (96-well) TPP, Nunc 
Scalpels Technic cut 
SuperFrost® Adhesion slides Thermo Scientific  
Tubes for cell culture (polystyrene, 15 and 50 ml) Falcon, Sarstedt 
Tubes for cell culture (polypropylene, 15 and 50 ml) Falcon 
Tubes for molecular biology, Safelock (1.5 and 2 ml) Eppendorf, Sarstedt 
 




Whatman paper Whatman 
4.2. Instruments and equipment 
Camera DC 300 FX Leica 
Camera DFC 290 Leica 
Cell counting chamber Neubauer Brand 
Cell culture incubator BBD 6220 Heraeus 
Cell culture sterile bench LaminAir HB 2448 Heraeus 
Controlled-freezing box   Nalgene 
Electrophoresis chambers for 
agarose gels 
  Peqlab 
Electrophoresis chambers for 
SDS-PAGE 
  BioRAD 
ELISA Reader SUNRISE A-5082 TECAN 
Freezer (-150 °C) Ultra low temperature freezer 
MDF-C2156VAN 
Sanyo 
Freezer (-20 °C) PremiumNoFrost Liebherr 




Fridge (+4 °C) Electrolux SANTO AEG 
Gel documentation BioDocAnalyze Biometra 
Heating block Thermostat plus Eppendorf 
Ice machine ZBE 70-35 Ziegra 
Incubator   Memmert 
 




Microcentrifuge  Eppendorf 
Micropipettes (2, 10, 100, 200, 1000 μl) Eppendorf 
Microscope DM 500 Leica 
Microscope inverted DM IRB Leica 
Microwave oven   Powerwave 
Microtome cryostat HM 355S Microm 
Modular tissue embedding 
center 
EC 350-1; EC 350-2 Microm 
PCR cycler T3 Thermocycler Biometra 
Pipetting assistant MATRIX Thermo Scientific 
Power supplier EV231 Peqlab 
Printer   Mitsubishi 
Pump VDE0530 Adam.Baumüller 
GmbH 




Refrigerated Microcentrifuge  Eppendorf 
Rotator   GLW 
Shaker IKA-Shaker MTS4 W. Krannich 
GmbH+Co.KG 
Sonifier   Dr. Hielscher 
GmbH 
Spectrophotometer ND-1000 NanoDrop 
Stereomicroscope MZ FL III Leica 
 




Transilluminator UV Star Biometra 
UV lamp EBQ100 isolated Leica 
Vortexer IKA ® Vortex IKA 
Water bath GFL 1003 W.Krannich 
GmbH+Co.KG 
Water purification system   Millipore 
Western Blot Documentation LAS-4000 Fujifilm 
Wet Transfer Apparatus Fastblot Biorad 
 
4.3. Common Chemicals and biological reagents 
Acetic acid Roth 
Agarose Invitrogen 
Ammonium persulfate (APS) Roth 
Bromdesoxyuridin (BrdU) Roche 
β-Mercaptoethanol Roth 
Bromphenol Blue Roth  
Chloroform Roth 
D(+)-trehalosedihydrat Roth 
DAKO Envision Kit DAKO 
DAPI (4´,6-diamidino-2-phenylindole) Sigma 
DEPC (diethyl pyrocarbonate) Roth 
DMEM GlutaMAX™ Invitrogen 
 




DMSO (dimethyl sulfoxide) Roth 
DNA Ladder  Fermentas 
DNase Roche 
DTT (DL-Dithiothreitol) Sigma 
EDTA (ethylenediaminetetraacetate) Roth 
EGTA (ethylene glycol tetraacetic acid) Roth 
EtBr (ethidium bromide) Roth 
Ethanol ChemieVertrieb Hannover 
Fast Start Taq DNA Polymerase (dNTPs pack) Roche 
FBS (fetal bovine serum) Invitrogen, Sigma 
GeneRulerTM 1 kb DNA ladder Fermentas 
Glycerol Sigma 
Glycine Roth 
HCl (hydrochloric acid) Roth 
HEPES Roth 
HOT FIREPol DNA Polymerase Solis BioDyne 
H2O2 (Peroxygen) Roth 
Immu-MountTM ThermoScientific 
Isopropanol J.T.Backer 
KAlS2O2 · 12H2O (potassium aluminium 
sulfate) 
Sigma 
KCl (potassium chloride) Sigma 
 





Lipofectamin 2000 Invitrogen 
Luminol Sigma 
Methanol J.T.Backer, Merck 
MgCl2 (Magnesium chloride) Roche 
MgSO4 (Magensium sulfate) Roth 
NaCl (sodium chloride) Roth 
NaHCO3 (sodium hydrogen carbonate) Merck 
NaOH (sodium hydroxide) Sigma 
Nicotinamid Sigma 
Nonidet-P40 (NP40)  Sigma 
Opti-MEM® Invitrogen 
p-Coumaric acid Sigma 
Peridoc acid (1%) Sigma 
PageRulerTM Prestained Protein Ladder Invitrogen 
Penicillin / streptomycin Invitrogen 
PFA (paraformaldehyde) Merck 
Polyacrylamide (30% Acrylamide/Bis) Roth 
Powdered Milk Roth 
Proteinase K  Roche 
Protease & Phosphatase Inhibitor cocktail 
tablets, EDTA free 
Roche 
 




Random hexamer primers IBA 
RevertAid H Minus Reverse Transcriptase Fermentas 
RNA sample buffer Fermentas 
RNase A (Ribonuclease A) Roche 
RNase Inhibitor Fermentas 
Roti®-Histokitt Roth 
Roti®-Phenol/Chloroform/Isoamylalkohol Roth 
Schiffs Reagent Sigma 
SDS (Sodium dodecyl sulfate) Sigma 
Streptavidin-biotinylated HRP GE Healthcare 




TRI Reagent Ambion 
Tris Roth 
Trisodium citrate Sigma 
Triton X-100 Sigma 
Trypan blue Sigma 
Trypsin/EDTA Invitrogen 
Tween 20 Sigma 
Xylol Roth 
 




4.4. Common buffers 
PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4) 
TBS (50 mM Tris-HCl, pH 7.4 and 150 mM NaCl) 
 
4.5. Laboratory animals 
Table 1: Mice strains 
Name Description Reference 
β-cateninfl(ex3) 
"gain-of-function" mutant; exon 3 is 
flanked by loxP sites, crossing with Cre 
expressing mouse strains will lead to 
stabilization of β-catenin  
(54) 
Pygo2fl 
"loss-of-function" mutant; inducible knock-
out due to insertion of loxP sites in the 3rd 




"loss-of-function"mutant due to chemically 






"gain-of-function" mutant; conditional 
transgenic K-RasV12 transgene that 
consists of a broadly active β-actin 
promoter, followed by a GFP [Green 
Fluorescence Protein] expression cassette 
flanked by two lox sites 
(137) 
Villin-Cre 
Cre recombinase under the direction of the 
mouse villin promoter for constitutive 
expression in the intestinal epithelium 
(138) 
Villin-CreERT2 
Tamoxifen-inducible Cre expression under 
the control of the Villin promoter for 









4.6. Human colon cancer cell lines 
The human colon cancer cell lines SW480 and HCT116 were purchased from 
ATCC. 
Table 2: Description of utilized human cell lines 
Name Description 
SW480 Colon adenocarcinoma cell line, established from a 50 year old male 
Caucasian (139); mutations: Apc, p53 and K-ras 
HCT116 Colon cancer cell line, established from an adult man (140); mutations: 
β-catenin, K-ras, PIK3CA 
 
4.7. Small interfering RNAs 
Small interfering RNAs (siRNAs) were obtained from Thermo Scientific.  
Table 3: Small interfering RNA used for transient transfection 
siRNA Name Target Sequence (5'-3')
ON-TARGETplus Non-targeting 
Pool 
Negative control siRNA with at least 4 
mismatches to any human, mouse, or rat gene 
ON-TARGETplusβ-catenin (pool) 
5´-GAU CCU AGC UAU CGU UCU U-3`
5´- GGUACGAGCUGCUAUGUUC-3` 
ON-TARGETplus Pygo2 (pool) 
5´-CUA CAG CAC UGG AGG UGG A-3`
5´-AAG CGA AGG AGG UCA AAU A-3` 
ON-TARGETplus BCL9-2 (pool) 
5´-GAA AGC CUC CCU CGC AGU U-3`             
5´-AAC CAG AUC UCG CCU AGC A-3` 
 
4.8. Oligonucleotides 
Oligonucleotides were synthesized by ©IBA GmbH, Göttingen. 
 




Table 4: Primer sequences used for genotyping 






5’-GCC ATC CCT TCA CGT TAG-3’
54 
wildtype: 619 bp  
mutant:331 bp 
MIN-sense-2 
primer  (mutation 
specific) 








5’-AGA ATC ACG GTG ACC TGG 
GTT AAA-3’ 
62 
wildtype: 570 bp 
mutant: 700 bp deltaN-Cat1051-
AS 
5’-CAT TCA TAA AGG ACT TGG 
GAG GTG T-3’ 
Pygo2-lox-S 5’-CCT GGG TTG CTT GTC TTC 
TG-3’ 
56
wildtype: 361 bp  
mutant: 405 bp Pygo2-ex3-AS 5’-GGA AGC AAA GGG ACA CAG 
AG-3’ 
HS133 5’-CGG CGA TGC CTA AGT ACG-
3’ 
60
wildtype: 275 bp 
targeted: 320 bp 
PCR 
deleted: 580 bp 
PY 1-4 5’-TGA AGC TTC AAG AGG CTT 
TTG-3’ 
PY1-5bn  5’-TGA AGT TTG AAA TAG CGA 
CGA G-3’ 
Villin-Cre-S  5’-CAA GCC TGG CTC GAC GGC 
C-3’ 
60
transgene: 220 bp 
 









5’-TAC AGT GCA ATG AGG GAC 
CA-3’ 
56
transgene: 207 bp 
 K-rasV12-MM-
3’AS 
5’-TCC TGA GCC TGT TTT GTG 
TCT-3’ 
 
Table 5: Primer sequences used for recombination analyses 
Name Sequence (5’-3’) Tm 
(°C) 
Product size 
BCAT-GF2 5’-GGT AGG TGA AGC TCA GCG 
CAG AGC-3’ 
60 
wildtype: 900 bp  
CatnbΔex3: 700 bp 
Catnbfl(ex3): 
2,8 kb 
LXR1-AS 5’-GGC CAG TAC TAG TGA ACC 
TCT TCG-3’ 
BCAT-AS5 5’-ACG TGT GGC AAG TTC CGC 
GTC ATC C-3’ 





KrasV12: 240 bp 
Ras 5-anti 5’-CCT ACG CCA CAA GCT CCA 
ACT AC-3’ 
GFP-5 5’-GAC CAC ATG AAG CAG CAC 
GAC-3’ 
GFP-3 5’-CGA ACT CCA GCA GGA CCA 
TG-3’ 
 
Table 6: Primer sequences used for qRT-PCR 
Name Sequence (5’-3’) Reference 
mHprt1 II S 5’-CCTAAGATGAGCGCAAGTTGAA-3’ http://www.rtprime
rdb.org 
mHprt1 II AS 5’-CCACAGGACTAGAACACCTGCTAA-3’ 
 











mAxin2 I S 5’-GCTCCAGAAGATCACAAAGAGC-3’ (141) 
mAxin2 I AS 5’-AGCTTTGAGCCTTCAGCATC-3’ 
mc-myc S 5’-GACCTAACTCGAGGAGGAGCTGGAA   
TC-3’ 
Besser, D. 
mc-myc AS 5’-AAGTTTGAGGCAGTTAAAATTATGG 
CTGAAGC-3’ 




mLgr5 I AS 5’-
GGGCCTTCAGGTCTTCCTCAAAGTCA-3’ 
mOlfm4 S 5’-CAGCTGCCTGGTTGCCTCCG-3’ (143) 
mOlfm4 AS 5’-GGCAGGTCCCATGGCTGTCC-3’ 
mAscl2 S 5’-AAGCACACCTTGACTGGTACG-3’ (143) 
mAscl2 AS 5’-AAGTGGACGTTTGCACCTTCA-3’ 
mMsi1 S 5’-GATGCCTTCATGCTGGGTAT-3’ (141) 
mMsi1 AS 5’-TAGGTGTAACCAGGGGCAAG-3’ 
mBmi1 S 5’-TCCCCACTTAATGTGTGTCCT-3’ (143) 
mBmi1 AS 5’-CTTGCTGGTCTCCAAGTAACG-3’ 




mProx1 S 5’-GCTCCAACATGCTGAAGACCTA-3’ (127) 
mProx1 AS 5’-GCTGCGAGGTAATGCATCTG-3’ 
 




mEphB2 S 5’-AGAATGGTGCCATCTTCCAG-3’ (141) 
mEphB2 AS 5’-GCACATCCACTTCTTCAGCA-3’ 
mEphB3 S 5’-CGTGAAAGTGGACACCATTG-3’ (141) 
mEphB3 AS 5’-CCAAGTAGAAGCCAGCCTTG-3’ 
mEphB4 S 5’-GCCATCAAGATGGGAAGATA-3’ (144) 
mEphB4 AS 5’-CACACTGGCCAAGATTTTCT-3’ 
 
Table 7: Antibodies used for immunohistochemistry 












BD Transduction Labs 
anti-Pygo2 rabbit 1:1500 Self-made (126) 
anti-Pygo1 rabbit 1:1500 Self-made (126) 
anti-BCL9 rabbit 1:1500 Self-made (126) 
anti-BCL9-2 rabbit 1:250 Self-made (126) 
anti-Prox1 rabbit 1:500 ab11941 Abcam 
anti-Sox9 rabbit 1:10.000 AB5535 Millipore 
anti-BrdU rat 1:100 ab6326 Abcam 
anti-Cleaved  
caspase 3 
rabbit 1:100 9661L CellSignaling 
Technology 
anti-Lysozyme rabbit 1:1000 18-0039 Invitrogen 
anti-ChromograninA rabbit 1:500 1782-1 Epitomics 
anti-c-myc rabbit 1:750 06-340 Millipore 
 




anti-pERK1/2 rabbit 1:400 4370 Cell Signaling 
Technology 
anti-rat biotinIgG goat 1:200 B7139 Sigma 
 
Table 8: Antibodies used for immunofluorescent staining 
Antibody Source Dilution Product No. Manufacturer 
anti-Pygo2 rabbit 1:1500 Self-made (126) 
anti-BCL9-2 rabbit 1:100 Self-made (126) 
anti-β-catenin mouse 1:1000 610154 Transduction 
anti-EphB2 goat 1:300 AF467 R&D Systems 
anti-EphB3 goat 1:300 AF432 R&D Systems 
anti-EphB4 goat 1:300 AF446 R&D Systems 
anti-BrdU rat 1:100 ab6326 Abcam 
anti-rat IgG Cy2 donkey 1:750 712-226-150 Jackson Immunoresearch
anti-rabbitIgG Cy3  donkey 1:750 711-166-152 Jackson Immunoresearch
anti-mouse IgG 
Cy2 
donkey 1:750 715-226-150 Jackson Immunoresearch
anti-goatIgG Cy3 donkey 1:750 705-165-147 Jackson Immunoresearch
 
Table 9: Antibodies for Western Blot 
Antibody Source Dilution Product 
No. 
Manufacturer 
anti-α-tubulin mouse 1:5000 T9026 Sigma
anti-BCL9-2 rabbit 1:100 Self-made (126)
 





anti-β-catenin rabbit 1:1000 Self-made (126)
anti-Pygopus2 rabbit 1:1000 Self-made (126)
anti-ERK1/2 rabbit 1:1000 9102 Cell Signaling Technology




















5.1. Animal experiments 
All animal experiments were performed in compliance with the German animal 
protection law (TierSchG) and approved by the animal welfare committees of the 
university medical centre Göttingen as well as the local authorities 
(Nierdersächsisches Landesamt). The mouse strains were maintained and bred in 
the animal facilities of the European Neuroscience Institute Göttingen (ENI). 
 
5.1.1. Generation of compound mutant mice 
In order to analyze the role of Pygo2 in the intestinal epithelium Villin-Cre 
transgenic mice were crossed with conditional Pygofl/fl and Pygofl/+ mice, resulting 
in constitutive deletion of Pygo2 in the embryonic intestinal epithelium. 
To determine the consequences of β-catenin stabilization and simultaneously of 
Pygo2 deficiency in the embryonic intestine these mice were further crossed with 
Catnbfl(ex3)/+ mice.  
Inducible Villin-CreERT2 animals were crossed with Catnbfl(ex3)/+ mice to induce 
β-catenin stabilization in the adult intestine. To analyze the contribution of Pygo2 
Villin-CreERT2+ Catnbfl(ex3)/+ mice were crossed with conditional Pygofl/fl and 
Pygofl/+ mice, respectively. The influence of a specific K-ras mutation (glycine to 
valine at codon 12)  on tumor development was examined by further crossing 
these mice with conditional KrasV12 transgenic mice resulting in compound 
Villin-CreERT2+ Catnbfl(ex3)/+ Pygofl/+/ Pygofl/fl KrasV12+ mice. 
Furthermore, constitutive Villin-Cre transgenic mice were bred with Pygofl/fl mice 








5.1.2. Induction of Villin-CreERT2 expression by Tamoxifen 
100 mg Tamoxifen were dissolved in 1 ml 100% EtOH and further diluted in sun 
flower oil to 10 mg/ml. For the induction of the Villin-CreERT2 recombinase 6 to 
8 weeks old mice were injected intraperitoneal with 1 mg Tamoxifen per 20 g 
bodyweight.  
 
5.1.3. DNA labeling in vivo 
In order to detect proliferating cells in living tissues BrdU labeling experiments 
were performed. Therefore, mice were injected either 2 hours (to score 
proliferation) or 48 hours (to score migration) prior to necropsy intraperitoneal 
with 100 μg/g of body weight of pre-warmed (37°C) BrdU (dissolved in sterile 
PBS). 
 
5.2. Histological Analysis 
5.2.1. Tissue processing for immunohistochemistry 
Tissue samples of transgenic and control mice were removed as quickly as 
possible and immediately transferred into ice-cold 4% paraformaldehyde/PBS. 
Fixation was done at 4°C overnight and samples were then washed with cold 
dH2O and transferred into 70% ethanol for long-term storage at 4°C. For 
dehydration and paraffinization the tissue samples were incubated in 75% EtOH, 
80% EtOH, 90% EtOH, 96% EtOH, 2 x 100% EtOH and 2 x xylol for 1.5 h each, 
followed by incubation in Paraffin for up to 12 h. The tissue was placed in 
embedding forms and embedded with fluid paraffin. Paraffin blocks were 
sectioned at 3 µm using a microtome. 
 
 




5.2.2. Hematoxylin and Eosin staining (H&E) 
In order to perform H&E staining, paraffin sections (3 µm) on adhesion slides 
were dewaxed in xylol (3 x 5 min), rehydrated through descending concentrations 
of alcohol (2 x 100%, 96%, 80% and 70% EtOH for 3 min each step) and washed 
in dH2O. Slides were then treated for 2 min with Mayer's hematoxylin and rinsed 
with tab water (5-10 min) for blueing. Subsequently, slides were stained with 
eosin for 2 min and dehydrated in a in a rising EtOH-series (70% and 80% EtOH 
for 10 sec, 96% and2 x 100% EtOH for 3 min) and xylol (3 x 3 min) and finally 
mounted with Roti®-Histokitt. 
 
5.2.3. Periodic acid Shiff staining (PAS) 
PAS staining was performed for detection of glycogen in tissues (purple color) 
(145;146). Paraffin sections were deparaffinized and rehydrated to water as 
described before (5.2.2) and then hydrolyzed for 10 min in 1 % periodic acid, 
rinsed with tab water for 10 min, washed in dH2O for 2 x 2 min and placed in 
Schiff reagent for 10 min. Subsequently sections were rinses for 5 min in warm (> 
35ºC) tab water, washed with dH2O for 2 min and counterstained with 
hematoxylin for 5 min, followed by 10-15 min blueing in tab water. Finally 
dehydration and mounting was done as described at 5.2.2.  
 
5.3. Immunological methods 
5.3.1. Immunohistochemistry 
For Immunostaining on tissue sections slides were dewaxed and rehydrated as 
described before (5.2.2). Subsequently antigen retrieval was performed by boiling 
in preheated antigen retrieval buffer (10 mM Tris, 1mM EDTA, pH 9.0 or 10 mM 
Trisodium citrate pH 6.0, 0.05 % Tween 20 in case of anti-β-catenin) for 15 min. 
While remaining in antigen retrieval buffer the samples were cooled down in a 
cold water bath to RT for about 1 h. After 3 x 5 min washing in dH2O endogenous 
peroxidase was blocked by 10 min incubation in 1% H2O2 followed again by 
 




washing in dH2O (5 min) and in 1 x PBS (2 x 5 min). Sections were then blocked 
for 30 min in IHC blocking solution (10% goat or horse serum, 1% BSA in 1x 
PBS) and incubated overnight (4°C) with the specific primary antibody (diluted in 
IHC blocking solution according to Table 7) in a humidified atmosphere. Slides 
were washed in 1 x PBS (3 x 5 min) and the corresponding secondary HRP-
conjugated antibody (DakoEnVision Kit) was applied for 45 min at RT in a 
humidified atmosphere. After washing again in 1 x PBS (3 x 5 min) staining was 
visualized with DAB according to manufacturer`s protocol and counterstained 
with Hematoxylin for 2 min followed by 10 min blueing with tab H2O. Stained 
sections were dehydrated and mounted as described before (5.2.2). 
 
5.3.2. Immunohistochemical detection of in vivo BrdU labeled cells 
Immunoperoxidase staining was used for the detection of in vivo BrdU labeled 
cells. Therefore tissue sections were processed as described in 5.2.2 and 5.3.1. 
After the primary antibody incubation according to Table 7, the sections were 
incubated with a biotin conjugated secondary antibody (diluted 1:200 in IHC 
blocking solution) for 60 min at RT. The slides were washed in 1 x PBS (3 x 5 
min) and subsequently HRP addition was performed. Therefore sections were 
incubated with streptavidin-biotinylated HRP (diluted 1:250 in IHC blocking 
solution) for 30 min at RT. After one 3 washing steps in 1 x PBS for 5 min the 
antibody-antigen complexes were detected using Gold and Silver tablets (1 Gold 
and 1 Silver tablet per 1 ml dH2O). Counterstaining, dehydration and mounting 
was performed as described in 5.2.2 and 5.3.1. 
 
5.3.3. Immunofluorescence 
In order to examine the co-distribution of two different proteins indirect 
immunofluorescence staining using specific unlabelled first (primary) antibodies 
and fluorophore labeled secondary antibodies was performed. For this purpose 
Paraffin sections were deparaffinized and rehydrated to water as described before 
(5.2.2) and incubated in preheated antigen retrieval buffer for 20 min. 
 




Subsequently sections were allowed to cool for an hour in a cold water bath and 
after washing in dH2O (3 x 3 min) and blocking for 30 min in blocking solution 
(10% goat, horse or rabbit serum, 0.1% Tween in 1x PBS) slides were incubated 
overnight at 4°C with the specific primary antibodies (diluted in blocking solution 
according to Table 8) in a humidified atmosphere. After washing (3 x 20 min in 
PBS/0.1% Tween) the secondary antibodies (diluted 1:750 in blocking solution) 
were applied for 45 min at RT in a dark humidified atmosphere. Samples were 
washed again in PBS/0.1% Tween (3 x 20 min) while counterstaining with DAPI 
(0.1 μg/ml) was performed in the second washing step. Finally sections were 
mounted with glass slides using Immu-MountTM mounting medium, dried for 3 h 
at 37°C and stored at 4°C in the dark. 
 
5.4. Molecular biological methods 
5.4.1. Isolation of genomic DNA (gDNA) for genotyping 
Mouse tail biopsies for extraction of total DNA were obtained from 3 week old 
mice and incubated in 50-100 μl lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM 
EDTA pH 8.0, 200 mM NaCl, 0,2 % SDS) containing fresh Proteinase K (200 
µg/ml) overnight at 55°C on a shaker. Afterwards genomic DNA was diluted 1:10 
with dH2O, boiled for 10 min at 95°C and centrifuged for 2 min at 13000 rpm. 
The supernatant was used for genotyping by PCR analysis. 
 
5.4.2. Isolation of genomic DNA from mouse intestinal tissues 
Genomic DNA from small intestine and colon of Tamoxifen treated mice was 
isolated to control the Cre mediated DNA recombination in transgenic mice. 
Therefore a small tissue piece was washed in cold PBS and incubated in 500 µl 
lysis buffer with Proteinase K (see 5.4.1) overnight at 55°C on a gentle shaker. To 
purify DNA from cell debris centrifugation was applied (13.000 rpm, 10 min). 
gDNA was precipitated from the supernatant by adding 1 ml ice-cold ethanol, 
shaking and subsequent centrifugation (13.000 rpm, 25 min, 4°C). The DNA 
 




pellet was washed with 500 µl 70 % ethanol and again centrifuged (13.000 rpm, 
10 min, 4°C). After air drying for 10 min at RT the DNA was resolved in an 
appropriate volume of dH2O.  
 
5.4.3. Polymerase chain reaction (PCR) 
For detection of Cre-mediated recombination at the specific gene loci PCR 
analyses (147) were performed. 1x Taq buffer without MgCl2, 0.6 units FastTaq 
DNA Polymerase, 0.5 μM primer each (according to Table 4 and Table 5), 0.2 
mM dNTPs each, 1.5-2.5 mM MgCl2 and 1 μl gDNA were mixed in a final 
volume of 15 μl per reaction. Genomic DNA of an appropriate tested transgenic 
mouse was used as positive and H2O as a negative control. Thermal cycling was 
initiated by 10 min denaturation at 95°C followed by 35 cycles of 95°C for 30 s, 
40 s primer annealing at the specific annealing temperature of the corresponding 
primer pair (Table 4 and Table 5) and 30-150 s elongation at 72°C according to 
the expected length of the PCR product (Table 4 and Table 5). Final elongation 
step was 10 min at 72°C and separation of DNA fragments occurred by horizontal 
agarose gel electrophoresis. 
 
5.4.4. Extraction and purification of total RNA using TRI Reagent® 
Isolation of RNA was performed from fresh or frozen small intestines (3 cm of 
duodenum) according to manufacturer’s instructions (Ambion Manual Version 
0610). Therefore tissue samples were homogenized in an appropriate volume of 
TRI Reagent and incubated for 5 min at RT. After addition of 200 μl chloroform 
per ml TRI Reagent and vigorously shaking for 15 sec samples were incubated for 
3 min at RT and subsequently centrifuged at 10500 rpm for 15 min (4°C). The 
aqueous phase containing RNA was carefully transferred into a fresh tube. 
Precipitation of RNA was achieved by adding 500 μl isopropanol per 1 ml TRI 
Reagent followed by moderate vortexing and 10 min incubation at RT. After 
centrifugation at 10500 rpm for 10 min (4°C) the supernatant was removed and 
the precipitated RNA pellet was washed with 1.5 ml 70% ethanol. The 
 




centrifugation step was repeated at 8000 rpm for 10 min and after complete 
removal of ethanol the pellet was air-dried for 5 min and dissolved in an 
appropriate volume of DEPC-dH2O. The RNA solution was stored at -80°C.To 
determine the concentration and quality of the RNA the absorbance at 260 and 
280 nm was measured using a NanoDrop ND-1000 Spectrophotometer. 
 
5.4.5. DNase treatment of RNA 
To digest residual gDNA 20 μg of total RNA was incubated for 90 min at 37°C 
with 2.5 μl 10x DNase buffer, 1.25 μl 20mMDTT, 0.5 μl RNase Out and 0.2 μl 
RNase-free DNase I in a final volume of 25 μl. Another 0.2 μl RNase-free DNase 
I was added and incubated for further60 min at 37°C. After adding nuclease-free 
H2O to a final volume of 100 μl RNA was precipitated byphenol:chloroform 
extraction. Therefore 100μl phenol:chloroform (20:1) Roti-Phenol were added to 
the mixture, vortexed for 15 s and centrifuged for 10 min at 13000 rpm (4°C). The 
upper aqueous phase was carefully transferred into a fresh tube and ammonium 
acetate was added to a final concentration of 2.5 M. RNA was precipitated with 
400 µl 100% EtOH followed by vortexing and 5 min incubation at RT. After 
centrifugation at 13000 rpm for 10 min (4°C) and removal of ethanol the RNA 
pellet was washed with 200μl 70% EtOH, centrifuged again (13000 rpm, 5 min, 
4°C), dried at RT for 2 min and resolved in 22 µl DEPC-dH2O. 
 
5.4.6. cDNA-Synthesis 
DNase treated RNA was reverse transcribed into complementary DNA (cDNA) 
using M-MuLV reverse transcriptase and random hexamer primers. Therefore 5μg 
RNA was incubated with 0.3 μg random hexamer primers in a final volume of 30 
μl for 5 min at 65°Candcooled on ice, rapidly. Subsequently 12 μl 5x reaction 
buffer, 3 μl 20 mM DTT, 1.5 μl RNase Inhibitor, 3 μl 10 mM dNTPs and 0.75 μl 
MMLV reverse transcriptase were added to a final volume of 60 μl and incubated 
at 25°C for 10 min followed by 60 min at37°Cfor. Reaction was terminated by 
heating at 70°C for 10 min and stored in aliquots at -20°C. 
 




5.4.7. Quantitative real-time PCR (qRT-PCR) 
The quantitative real-time PCR protocol was kindly provided by Prof. Dr. Steven 
Johnsen, Dept. of Molecular Oncology, Georg August University Göttingen, 
Germany and adapted by Dipl. Biol. Maria Wiese. 
SYBR Green real-time PCR was performed in order to assess the gene expression 
in intestinal tissues. Therefore appropriate cDNA samples (20 ng) and primers 
(0,3 pmol/μl) were added to 8 µl GREEN PCR Master Mix (75 mM Tris-HCl pH 
8.8, 20 mM (NH4)2SO4, 0.01% Tween-20, 3 mM MgCl2,0.2 mM dNTPs, 20 U/ml 
HOT FIREPol DNA Polymerase, 0.25% TritonX-100, 500 mM D(+)-Trehalose 
Dihydrat, Cybr Green (1:80000)) in a final volume of 10 µl and loaded in 
duplicates onto a 96-well PCR-plate. Fluorescence was measured with an AB7300 
Real-Time PCR System (Applied Biosystems). Gene expression was calculated 
relative to the mRNA levels of Hprt1 using the 2-∆∆Ct method (148). SDS Software 
2.2 and Microsoft Excel were used for data analysis and graphically presentation.  
 
5.5. Biochemical methods 
5.5.1. Isolation of whole cell protein lysates from adherent cells 
For preparation of whole cell lysate protein extracts from adherent colon cancer 
cells Protease and Phosphatase Inhibitors were added to ice-cold cell lysis buffer 
(RIPA buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40). 
Before cell lysis, cells grown in 10 cm plates were washed in ice-cold PBS. 
Subsequently 500 μl of 1 x RIPA buffer were added, cells were scraped off with a 
cell scraper and transferred to a fresh tube. The cells were sonicated on ice for 15 
sec, centrifuged at 4°C for 15 min (13000 rpm) and the protein containing 
supernatant was transferred to a fresh tube. For storage at -20°C or direct 
processing for SDS polyacrylamide gel electrophoresis (SDS-PAGE) the 
appropriate amount of 4 x protein sample buffer (100 mM Tris-HCl pH 8.0, 4% 
SDS, 0.2% Bromphenol blue, 20% Glycerol) was added and samples were 
incubated for 5 min at 95°C.  
 
 




5.5.2. Western blot  
To analyze protein expression SDS-PAGE under denaturating conditions was 
used for separation of proteins followed by Western blotting. Therefore protein 
samples were heated for 5 minutes at 95°C and centrifuged for 5 seconds in a 
microcentrifuge. An appropriate sample amount or prestained molecular weight 
markers (5μl) were loaded into each lane of 6 or 12% polyacrylamide gels and the 
gels were run at 100-200V (constant voltage) in SDS-PAGE running buffer 
(2.5 mM Tris, 19.2 mM Glycine, 0.01% (w/v) SDS) for up to 4 h. The gels were 
soaked in transfer buffer (2.5 mM Tris pH 8.3, 19.2 mM Gylcine, 20% (v/v) 
Methanol) and the proteins were transferred to methanol activated Hybond-P 
PVDF membranes at 500 mA for 1.4 h in a wet blot device at 4°C. After 
electroblotting unspecific binding sites were blocked by immersing the membrane 
in blocking solution (5% powdered milk in TBS-T or 5% BSA in TBS-T). 
Blocked membranes were washed 3 times with TBS-T (TBS with 0.05% (v/v) 
Tween 20) and incubated with the primary antibody (diluted according to Table 9 
in blocking solution depending on the instructions of the antibody manufacturer) 
o/n at 4°C. After washing in TBS-T (3 x 5 min) the appropriated horseradish 
peroxidase (HRP)-coupled secondary antibody was applied for 1 h at RT. Finally 
membranes were washed another 3 times with TBS-T and antibody-antigen 
complexes were detected using ECL detection solution by mixing equal volumes 
of Solution A (2.5 mM Luminol, 0.4 mM p-coumaric acid, 0.1 M Tris-HCl pH 
8,5) with Solution B (0.05% (v/v) 35% H2O2, 0.1 M Tris-HCl pH 8,5) to yield 
sufficient volume to cover the membrane. Solution was incubated for 2 min at RT 
and signals were detected with the LAS-4000 imaging system. For long-term 
storage, membranes were air dried and stored at -20°C. Reactivation of 
membranes was done by incubation in methanol (1 min). 
For stripping, membranes were washed in TBS-T (3 x 5 min) and incubated in 
freshly prepared stripping buffer (0.15 M glycine pH 2.5, 0.4% SDS) for 2 x 15 
min. Afterwards membranes were briefly washed in 1 M Tris pH 6.8 followed by 
3 x 5 min in TBS-T. 
  
 




5.6. Cell culture 
5.6.1. Cell culture of human colon cancer cell lines 
Human colon cancer cell lines were cultured in 20 ml DMEM supplemented with 
10% FCS in a middle-sized culture flask (75 cm2 adherence surface) at 37°C (5% 
CO2) in a humidified atmosphere. Every 3-4 days, depending on their confluency, 
the medium was removed and cells were split 1:5 to 1:10. Therefore the cells were 
washed once with PBS and detached with 3 ml trypsin by incubation at 37°C for 5 
min (5% CO2). Detached cells were resuspended in fresh culture medium and 
spread in a new culture flask.  
For long-term storage, cells were cryopreserved in freezing medium (DMEM 
containing 20% FCS and 10% DMSO) at -150°C. To re-culture the cryopreserved 
cells, cryovials were thawed at 37°C in a water bath and transferred into a 50 ml 
Falcon tube containing 10 ml PBS. Afterwards, the cells were centrifuged at 1000 
rpm for 3 min and resuspended in pre-warmed culture medium. The cell amounts 
were determined using Neubauer hemocytometer. 
 
5.6.2. Transient RNA interference  
For transient protein knock down, transfection with short interfering RNA 
(siRNA) (Table 3) was performed using Lipofectamin 2000 Transfection Reagent 
according to manufacturer’s instructions. Prior transfection 2.5 x 105 (SW480) or 
2.25 x 105 (HCT116) cells per ml were seeded in 6 cm culture plates. Following 
the overnight incubation, 1 ml Optimem containing the specific siRNA at a final 
concentration of 25 pmol and 10 µl Lipofectamin 2000 Transfection Reagent were 
added to the cells. After 72 hours whole cell protein lysates were isolated and the 









5.6.3.  MTT assay  
To analyze viable cells by MTT assay, SW480 and HCT116 cells were seeded in 
96-well microtiter plates at a density of 5000 cells/well in a final volume of 80 μl 
DMEM in triplicates. After incubation overnight at 37°C (5% CO2) in a 
humidified atmosphere, cells were treated with siRNA for 24 h, 48 h or 72 h in the 
culture medium for functional assays (Table 3). The untreated cells (appropriate 
volume of buffer solution was added) served as controls. The media were changed 
every 24 h. After the respective incubation time 10 µl of MTT stock solution (5 
mg/ml in 1x PBS) was added to the cells/control wells without cells and incubated 
for 3.5 h at 37°C (5% CO2) in a humidified atmosphere. The media was carefully 
removed and primary cells were incubated with 150 µl MTT solvent (33% 
DMSO, 5% formic acid, 62% Isopropanol) per well for 15 min at RT (shaker). 
Absorbance (590 nm) was measured in an ELISA reader. Each assay was 
performed in triplicate. 
 
5.7. Statistics  
Statistical significances of qRT-PCRs and BrdU incorporation was calculated by 
the conventional t-test using Microsoft Excel. The SPSS 21.0 software was used 
to calculate significant differences in Kaplan-Meier survival or adenoma 
development with the P log-rank test. 






6.1. Consequences of loss of Pygo2 in the intestine 
6.1.1. Villin-Cre mediated deletion of Pygo2 in the intestinal epithelium 
of adult mice 
To achieve conditional ablation of Pygo2 in the mouse small intestine and colon, 
mice carrying loxP-flanked Pygo2 alleles (Pygo2fl; W. Birchmeier, unpublished) 
were crossed with mice carrying Cre recombinase under control of the Villin 
promoter (138). Genetic recombination is expected to initiate at embryonic day 
(E) 9 in the visceral endoderm, and by E12.5 in the entire intestinal epithelium 
(138).  
Villin-Cre+ Pygo2fl/fl mice were born at normal Mendelian ratios and no 
embryonic lethality was observed. Adult Villin-Cre+ Pygo2fl/fl mice were viable 
and fertile and did not show any macroscopic phenotype.  
Histological no major alterations in crypt villus architecture after epithelial loss of 
Pygo2 could be observed. Using our specific antibody (126) deletion of Pygo2 in 
the epithelial cell population was confirmed by immunohistochemistry on sections 
of small intestine and colon of adult Villin-Cre+ Pygo2fl/fl mice. In contrast Pygo2 
was still expressed in mesenchymal cells and cells of the smooth muscle layer 
(Figure 5).  
Loss of Pygo2 was almost completely in the epithelial cell population of the 
proximal small intestine from Villin-Cre+ Pygo2fl/fl mice, indicating that the 
recombination efficiency was nearly 100 %. Single clusters of epithelial cells 
which still expressed Pygo2 were detected in the distal small intestine and the 
colon, suggesting that these cells escaped from recombination (data not shown).  
Heterozygous Villin-Cre+ Pygo2fl/+ mice, thus animals with half gene dosage, still 
expressed Pygo2 in intestinal epithelial cells and did not have an apparent 
phenotype (data not shown). Therefore, these mice also served as controls as 
indicated. 
 




the normal intestinal architecture in adult mice. 
ntestinal epithelium of Pygo2-deficient 
mice. Efficient Cre-mediated recombination exclusively in the intestinal epithelium of adult 
.1.2. Pygo2 is not required for normal development of the embryonic 
intestine 
opment of the intestinal epithelium starts around E14.5 and is 
completed around E18.5 when villi are formed by mucosal invaginations (77). 
 the villi (Figure 6). Moreover, the 
expression pattern and subcellular location of β-catenin were not altered by the 
Thus, Villin-Cre recombinase successfully drives the recombination of 
conditional floxed Pygo2 alleles specifically in the intestinal epithelium and the 
resulting loss of Pygo2 expression does not have any obvious consequences for 
Figure 5: Absence of Pygo2 protein expression in the i
Villin-Cre+ Pygo2fl/fl mice was confirmed by immunohistochemical staining with a Pygo2 specific 
antibody. Scale bars: 50 µm. 
 
6
In mice the devel
Cell division is restricted to the proliferative pockets at the base of these 
invaginations which develop to mature crypts in the first weeks after birth (77). 
Since Pygo2 is already ubiquitously expressed in the embryonic intestine (126) 
the consequences of Pygo2 loss for the development of the intestinal epithelium 
were analyzed by immunohistochemistry on tissue sections from Villin-Cre+ 
Pygo2fl/fl and control mice at E18.5. H&E staining did not reveal any defects in 
intestinal development in the absence of epithelial Pygo2 which was confirmed by 
Pygo2 immunohistochemistry (Figure 6). 
In addition, as examined by BrdU labeling experiments, proliferation was 
restricted to the pockets at the base of
 




Figure 6: Normal development of the embryonic intestine in the absence of Pygo2. 
Immunohistochemical staining as indicated of embryonic small intestines from Villin-Cre+ 
Pygo2fl/fl and control mice at E18.5. Scale bars: 50 µm. 
 
nt/β-catenin signaling is absolutely required for the maintenance of intestinal 
tinal homeostasis in adult mice were further examined in detail by 
ntrols (Figure 7). Quantification 
loss of Pygo2. β-Catenin was predominantly found at the membrane of epithelial 
cells in both Villin-Cre+ Pygo2fl/fl and control mice with the strongest expression 
in the highly proliferating intervillous regions (Figure 6). 
These results indicate that epithelial Pygo2 is apparently not required for the 
normal embryonic intestinal development. 
6.1.3. Pygo2 is dispensable for intestinal homeostasis 
W
homeostasis (46;49). Therefore, the consequences of loss of epithelial Pygo2 for 
intes
histological and immunohistochemical analysis.  
BrdU labeling experiments revealed normal proliferation in Pygo2-deficient 
intestines. Tthe location and size of the proliferative compartment in the crypts of 
Villin-Cre+ Pygo2fl/fl mice were comparable to co
of the number of BrdU positive cells per crypt in the small intestine and colon did 
not reveal significant differences between Villin-Cre+ Pygo2fl/fl and control mice 
(Figure 7).  
 










Figure 7: Loss of Pygo2 does not affect intestinal homeostasis and proliferation. 
Immunohistochemical analysis of BrdU, ChromograninA and Lysozyme and staining with 
periodic acid-Schiff (PAS) for labeling of proliferative, enteroendocrine, Paneth and Goblet cells, 
respectively. The staining indicates that all cell types were present at the expected location in 
Pygo2-deficient tissues. Quantification of the number of positive cells for any staining revealed no 
significant difference between Villin-Cre+ Pygo2fl/fl and control mice. Scale bars: 200 µm. 
 
The presence and correct localization of the differentiated intestinal cell lineages 
in Pygo2-deficient intestines was further confirmed using specific marker staining 
(Figure 7). The quantification of these staining showed that the numbers of Paneth 
cells (Lysozyme positive), Enteroendocrine cells (ChromograninA positive) and 
Goblet cells (PAS positive) were comparable between control and Villin-Cre+ 
Pygo2fl/fl mice (Figure 7).  
The regulation of intestinal homeostasis by the canonical Wnt/β-catenin signaling 
pathway (including proliferation and migration) is in part mediated by its ability 
to promote the transcription of the EphB2/B3 receptors and inhibit that of ephrin-
B ligands (58;149;150). In agreement with this, EphB and ephrin-B genes are 
expressed in countergradients along the crypt axis. The expression of EphB 
receptors can be found in intestinal crypts where Wnt/β-catenin signaling is high 
and is gradually lost when epithelial cells migrate upward the villi (58;149;150).  
In this context the effect of conditional deletion of Pygo2 in the intestinal 
epithelium on the expression of EphB receptors was examined by 
immunofluorescence staining using specific antibodies for EphB2, EphB3 and 
EphB4. As shown in Figure 8 all three EphB receptors had comparable expression 
patterns in the small intestine and colon of Villin-Cre+ Pygo2fl/fl mice and control 
mice (Villin-Cre- Pygo2fl/fl). This could be further confirmed by quantitative real-
time (qRT) PCR analysis of isolated intestines from Pygo2 deficient and control 
mice. Similar to the immunofluorescence staining no significant differences in 
mRNA expression levels of EphB2, EphB3 and EphB4 were detected in these 
tissues (Figure 8D). 
Furthermore, the ability of Pygo2 deficient epithelial cells to migrate normally up 
the crypt-villus axis was examined. Therefore the mice were injected with BrdU 
and sacrificed after 2 or 48 hours for immunohistochemical analysis. As shown in 
Figure 9A labeled cells from both Villin-Cre+ Pygo2fl/fl mice and control 
 




  hours 
fter labeling (Figure 9B).  
pt compartment as well as their differentiation and 
littermates migrated to the similar positions on the villi 48 hours after labeling. 
The rate of migration of epithelial cells was defined by the cumulative frequency 
of BrdU-positive cells along the crypt-villus axis and did not reveal significant 
differences between Pygo2-deficient and control small intestines 2 or 48
a
Quantification of the number of BrdU-positive cells revealed an average 
decreased proliferation of about 30 % in the small intestine of Pygo2 deficient 
mice compared to the control littermates 48 hours after labeling (Figure 9C). 
However, due to inter-individual differences this decrease was not significant. 
Taken together, these findings indicate that in the intestine the proliferation of the 
progenitor cells in the cry
migration do not depend on Pygo2.  
 
 










Figure 8: Comparable expression of EphB receptors in intestinal tissues from Villin-Cre+ 
Pygo2fl/fl and control mice (Villin-Cre- Pygo2fl/+). Sections from proximal and distal small 
intestinal and colon were stained with specific antibodies for BrdU (green) and EphB2 (A), EphB3 
(B) or EphB4 (C) (red), respectively. Scale bars: 50 µm. (D) qRT-PCR analysis for EphB receptor 
mRNAs was performed on 3 individual mice per genotype. The bars represent transcript 
expression relative to one control animal and the mean of at least 3 qRT-PCRs with their standard 
error. 
 
Figure 9: Deletion of Pygo2 does not influence the migration of small intestinal epithelial 
cells. Cell migration was assessed by labeling cells with BrdU. Mice were sacrificed 2 or 48 hours 
after labeling. (A) Immunohistochemical analysis of BrdU revealed that control and Pygo2 
deficient cells incorporated the label at similar frequencies and positions 2 hours after BrdU 
injection. In addition, proliferating cells from both Pygo2-deficient and control animals migrated 
to the similar positions on the villi 48 hours after labeling. Scale bars: 100 µm. (B) The migratio
of BrdU-labeled cells was quantified, and a cumulative frequency plot was generated. The 
distribution of the labeled cells after 2 hours (dashed lines) and 48 hours (solid lines) was not 
significantly different between control (red lines) and Villin-Cre+ Pygo2fl/fl (blue lines) tissues. (C) 
Quantification of the number of BrdU+ cells per crypt-villus unit in Villin-Cre+ Pygo2fl/fl and 
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Pygo2 deficient intestines 
ygo2 is a nuclear cofactor of β-catenin but does not seem to be essential in the 
normal intestine. In order to analyze the physiological Wnt target gene activity in 
Pygo2 deficient intestines the RNA expression levels of known Wnt/β-catenin 
target genes was examined by qRT-PCR analysis and compared with control 
mice.  
Axin2 and c-myc are classical Wnt/β-catenin target genes (151-154) but their 
expression in the intestine does not seem to be markedly regulated by Pygo2 since 
no clear differences in the mRNA expression levels of Axin2 and c-myc were 
observed after epithelial loss of Pygo2 (Figure 10).  
The HMG-box transcription factor Sox9 is expressed in intestinal stem and 
progenitor cells and in Paneth cells, whereas the homeobox transcription factor 
Prox1 is supposed to be expressed in a small number of intestinal epithelial cells 
probably representing enteroendocrine cells. Both genes were shown to be 
regulated by Wnt/β-catenin signaling pathway in the intestine (155;156). 
However, following deletion of Pygo2 the expression of Prox1 and Sox9 mRNAs 
were unchanged compared to control mice (Figure 10). The mRNA expression of 
Sox9 was very variable in control as well as in Pygo2 deficient animals (Figure 
10). 
Due to the critical role of Wnt/β-catenin signaling in the regulation of epithelial 
control mice was examined 2 and 48 hours after labeling. The results represent the means of 3 (2 
hours) or 5 (48 hours) individual mice per genotype. 15 crypt-villus units per mice were counted.  
 
6.1.4. Decreased expression of the intestinal stem cell marker Msi1 in 
P
stem cells in the intestinal tract (70) the expression of selected intestinal stem cell 
markers was further analyzed. The expression of Lgr5, Olfm4 and Acsl2 is 
restricted to the small cycling CBC cells located at the crypt bottom intermingled 
with Paneth cells (68;157;158). Although all three genes were identified to be 
Wnt/β-catenin targets (55;68;68;157;158;158;159) intestinal deletion of Pygo2 did 
not affect their expression levels (Figure 10). Due to high standard deviations and 
interindividual differences the apparent upregulation of Ascl2 in Pygo2 deficient 
 




pregulated (on average ~ 7 fold) following loss of Pygo2 (Figure 10). 
ince control and Villin-CreERT2+ Pygo2fl/fl mice expressed similar 
intestines was not consistent. In contrast the expression of Musashi-1 (Msi1), 
another CBC cell specific stem cell marker (160;161) was significantly 
u
Expression of the polycomb protein Bmi-1, which is expressed in small intestinal 
stem cells located at the +4 position (63), was unchanged in Pygo2 deficient 
intestines (Figure 10). 
We have previously shown that the expression of another nuclear cofactor of β-
catenin, BCL9-2, is not influenced by siRNA mediated knock-down of Pygo2 in 
human colon cancer cells (126). This could be confirmed in vivo in the normal 
intestine s
levels of BCL9-2 (Figure 10).  
Taken together these findings indicate that in the intestine Pygo2 does not regulate 
the expression of Wnt/β-catenin target genes and ISC marker but may be involved 
in the regulation of Msi1 expression.  
Lgr5 Olfm4 Ascl2 Msi1 Bmi1
9
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Figure 10: Expression analyses of intestinal genes in Pygo2 deficient intestines. Quantitative 
real time PCR analyses of Wnt/β-catenin target genes, BCL9-2 and intestinal stem cell markers. 
cDNA was isolated from 3 individual mice per genotype and the relative mRNA expression was 
calculated with regard to one control animal. Shown are the means of at least 3 qRT-PCRs and 



































































































titutive activation of Wnt/β-catenin signaling can 
be induced in the intestinal epithelium. In these mice exon 3 of β-catenin, which 
ration and intestinal adenoma formation (54;162). 
fl(ex3)  fl 
 intestines were undistinguishable from 
that of control mice (Villin-Cre ) (see 6.1.1.), Pygo2 deficient animals (Villin-Cre+ 
Catnbfl(ex3)/+ Pygo2fl/fl) were compared with heterozygous Villin-Cre+ Catnbfl(ex3)/+ 
Pygo2fl/+ mice.  
We found that Villin-Cre+ Catnbfl(ex3)/+ Pygo2fl/+ mice died around birth, indicating 
that stabilization of β-catenin may lead to developmental lethal defects in the fetal 
intestines. To prove this, the fetal intestinal epithelium of Villin-Cre+ Catnbfl(ex3)/+ 
Pygo2fl/+ animals was analyzed in more detail at E18.5, shortly before birth.  
Villin-Cre+ Catnbfl(ex3)/+ Pygo2fl/+ mice exhibited dramatic developmental defects 
characterized by disruption of normal epithelial morphogenesis and strong 
hyperproliferation as examined by H&E staining and immunohistochemistry for 
BrdU (Figure 11E and F). The intervillous regions of these mice showed 
increased expression of β-catenin compared to that of control mice (Villin-Cre- 
Catnbfl(ex3)/+ Pygo2fl/fl). Moreover increased β-catenin expression was found in 
many cells of the hyperproliferative villi of Villin-Cre+ Catnbfl(ex3)/+ Pygo2fl/+ fetal 
intestines, whereas control villi displayed predominantly membranous β-catenin 
staining (Figure 11H). 
6.2. Loss of Pygo2 is able to compensate the developmental 
defects caused by activated Wnt/β-catenin signaling in the 
embryonic intestine 
In order to analyze the potential role of Pygo2 in intestinal tumorigenesis a mouse 
model was analyzed, where cons
contains the essential phosphorylation sites targeting it for proteasomal 
degradation, was flanked by loxP sequences (Catnbfl(ex3); (54). Deletion of this 
exon by Cre recombinase thus produces a stabilized β-catenin protein leading to a 
hyperactivation of Wnt-signaling. Stabilization of β-catenin in the intestinal 
epithelium leads to hyperprolife
Catnb mice were intercrossed with Villin-Cre Pygo2 and the macroscopic 
and microscopic phenotypes were examined.  
Since heterozygous Villin-Cre+ Pygo2fl/+
-
 




mice survived birth and did not show any apparent abnormalities. This 
prompted us to assume that the loss of Pygo2 in these mice has rescued the effects 
 Pygo2 completely restored the morphological defects 
caused by stabilized β-catenin and decreased the proliferation to normal levels, 
The efficient loss of Pygo2 expression in the intestinal epithelium of Villin-Cre+ 
Catnbfl(ex3)/+ Pygo2fl/fl mice at E18.5 was confirmed by Pygo2 
immunohistochemistry (Figure 11H). Interestingly, Villin-Cre+ Catnbfl(ex3)/+ 
fl/fl Pygo2
of activated Wnt/β-catenin signaling in the embryonic intestine. Indeed, intestinal 
tissues from Villin-Cre+ Catnbfl(ex3)/+ Pygo2fl/fl mice were undistinguishable from 
control intestines. Loss of
restricted to the intervillous region as in control animals (Figure 11I and J). 
Furthermore the increased expression of β-catenin in the epithelium of Villin-Cre+ 
Pygo2fl/+ Catnbfl(ex3)/+  intestines was rescued by Pygo2 ablation (Figure 11L).  
Figure 11: Deletion of Pygo2 completely rescues embryonic defects in gastrointestinal 
development induced by stabilized β-catenin. Stabilization of β-catenin in the embryonic 
intestinal epithelium using Villin-Cre is perinatal lethal and leads to developmental defects and 
increased proliferation. Loss of Pygo2 in the intestinal epithelium of these mice completely 
restored these defects, as examined at E18.5.  Scale bars: 100 µm. 
 
 




Furthermore ablation of Pygo2 is obviously able to 
compensate this hyperactivation of Wnt/β-catenin signaling and completely 
tina
 
6.3.1. Effects of temporally controlled stabilization of β-catenin in the 
intestinal epithelium 
Due to the perinatal lethality of Villin-Cre+ Catnbfl(ex3)/+ Pygo2fl/+mice the effects 
of stabilized β-catenin in the adult intestine were studied using a Tamoxifen 
inducible Villin-CreERT2 mouse strain (138). Cre mediated excision was induced 
by intraperitoneal injection of Tamoxifen for 5 days and the mice were sacrificed 
at two different time points after induction (18 and 34 days). The recombination 
of exon 3 of β-catenin after the induction of the Cre expression was confirmed by 
PCR analyses using genomic DNA isolated from the small intestine and colon of 
Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ (Figure 12B).  
 
These results show that constitutive activation of the Wnt/β-catenin signaling 
pathway in the fetal intestine dramatically disturbs the development of the 
intestinal epithelium. 
restores the normal intes l architecture. 
 
6.3. Role of Pygo2 in intestinal tumorigenesis 
Pygo2 was found to be upregulated in adenoma of ApcMin/+ mice as well as in 
human colon cancer (126) indicating a potential role in intestinal tumorigenesis. 
To further investigate this assumption two mouse models were established in this 
work, which allowed us to analyze if Pygo2 is involved in the development of 
intestinal tumors in the context of active Wnt/β-catenin signaling. 
 




thelium prevents β-catenin 
mediated hyperproliferation. (A) 18 days after induction with Tamoxifen stabilization of β-
atenin in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ intestines leads to dramatically enlarged crypts 
and increased proliferation as examined by H&E and BrdU staining. IHC of Pygo2 shows 
Figure 12: Conditional ablation of Pygo2 in the intestinal epi
c
 




upregulation in the hyperproliferative epithelium of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice 
and loss of Pygo2 protein in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl following Cre induction. 
Crypts that escaped recombination of Pygo2 show hyperproliferation (right panel). Scale bars: 200 
µm. (B) Representative PCR analysis using genomic DNA derived from small intestine and colon 
of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice confirms successful recombination of exon 3 of β-
catenin, 18 and 34 days after Tamoxifen induction. Genomic DNA from tail biopsies of the 
corresponding mice served as control. NTC: no template control.  
 
18 days after Tamoxifen injection the small intestine of Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/+ appeared normal in length but consistently wider than that of 
control mice (Villin-CreERT2-). The colon did not display any apparent 
macroscopic phenotype. Histopathological studies revealed an enlarged crypt 
compartment all along the small intestine of mutant mice but most prominent in 
the proximal part (Figure 12A, H&E staining). Moreover, occasionally small 
cystic structures were observed between the normal villus epithelium. These 
morphological changes were associated with hyperproliferation and increased 
apoptosis, as examined by BrdU labeling (Figure 12A) and immunostaining for 
Cleaved Caspase 3 (Figure 13). At this early time point no adenomas were 
observed. 
Figure 13: Increased apoptosis following mutational activation of β-catenin in intestinal 
 
epithelial cell. IHC for Cleaved Caspase 3 on tissue sections from control, Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/+ and Pygo2fl/fl mice, respectively. Mice were sacrificed at day 18 or day 34 
after Cre induction. Scale bars: 100 µm. 
 




sions were found in the distal small intestine but there was some preservation of 
normal intestinal architecture at the crypt bases and villi tips. However, the crypt 
+ 
Figure 14: Intestinal hyperproliferation induced by stabilized β-catenin shows an 
upregulation of Pygo2. Co-immunofluorescence staining of Pygo2 (red) and β-catenin (green) on 
intestinal sections of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ and Pygo2fl/fl mice, respectively, 34 
days after Tamoxifen induction. Scale bars: 100 µm. 
 
Thus, Pygo2 is already upregulated in very early stages of intestinal tumorigenesis 
 by the hyperproliferation induced by stabilized β-catenin, further 
indicating a role in the development of intestinal tumors. 
34 days after induction the normal intestinal architecture of Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/+ mice was completely disturbed and the proximal part of the 
small intestine was grossly thickened (Figure 15A). Microscopic analysis revealed 
that these mice display severe intestinal pathology and adenoma development in 
the proximal part of the small intestine (Figure 15B). Smaller adenomatous 
le
compartment was still slightly enlarged and hyperproliferative (data not shown).  
In Villin-CreERT2 Catnbfl(ex3)/+ Pygo2fl/+ mice both the intestinal 
hyperproliferations 18 days after induction and the more severe pathology 34 days 
after induction showed an upregulation of Pygo2 compared to normal epithelium 
(Figure 12A, Figure 14 and Figure 15B).  
represented
 




he assumption that Pygo2 is involved in Wnt/β-catenin dependent intestinal 
 
morphologically indistinguishable (Figure 12A, Figure 15B). Histopatholgical 
Interestingly, occasional clusters of hyperproliferative cells (Figure 12A) and 
nascent microadenomas of different size (Figure 15B) could be identified in 
double mutant mice, raising the assumption that some cells escaped the 
recombination of Pygo2. Indeed immunohistochemical analysis revealed that 
these cells still expressed Pygo2 (Figure 12A) and gradually developed to small 
adenomas after 34 days, which exhibited at least small clusters of Pygo2 positive 
cells (Figure 14; Figure 15B). 
12 weeks after Cre induction these adenomas increased in number and size. 
Macroscopically the proximal small intestine was strewn with several hundreds of 
adenomas of different sizes, reaching from < 2 mm to 4 mm, and several isolated 
small adenomas (< 2 mm) were found in the distal small intestine. Histological 
6.3.2. Pygo2 is required for intestinal hyperproliferation and adenoma 
development induced by stabilization of β-catenin 
T
tumorigenesis was further examined in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl 
mice. Here both Pygo2 alleles were deleted following induction with Tamoxifen, 
leading to a complete ablation Pygo2 in intestinal epithelial cells with stabilized  
β-catenin (Figure 12A and Figure 15B). 
Macroscopically the intestines of these mice appeared normal. Histological 
analysis showed that the loss of Pygo2 was able to rescue the phenotypes of 
stabilized β-catenin since the intestines of wildtype and double mutant mice were
changes associated with stabilization of β-catenin such as the increased crypt 
cellularity and proliferation were absent in the double mutants. Proliferative cells 
were restricted to the crypt compartment, comparable to control epithelium 
(Figure 12A and Figure 15B).  
examination revealed that these adenomas closely resembled that found in 
ApcMin/+ mice (Figure 16A). No invasive carcinomas were identified.  
 
 











igure 15: Stabilization of β-catenin in the intestinal epithelium leads to Pygo2 dependent 
tumor development. (A) Low magnification field of the proximal small intestine of Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+, Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl and control mice (H&E 
staining). Scale bars: 1 mm. (B) Immunohistochemical staining of intestinal sections from mice 
with the indicated genotypes 34 days after Cre induction. The last panel shows a small adenoma 
developed from crypts that escaped Pygo2 recombination. Scale bars: 200 µm. Inserts show higher 
magnifications.  
 
Immunohistochemistry for Pygo2 on serial sections of intestinal tissues from these 
mice confirmed the presence of Pygo2 expressing cells in the adenomatous 
tumors indicating that they developed from intestinal crypt cells that escaped the 
deletion of Pygo2 (Figure 16).  
Importantly, loss of Pygo2 significantly increased the survival of mice harboring a 
stabilized β-catenin protein (p < 0.05, log-rank test). Villin-CreERT2+ Catnbfl(ex3)/+ 
Pygo2fl/+ mice did not survive more than 35 days after Cre induction, whereas 
Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl mice died between day 71 and 91 after Cre 
induction (Figure 16B). 
 
Taken together, these findings strongly implicate that Pygo2 is essential for 
intestinal tumorigenesis induced by stabilized β-catenin. 
F





Figure 16: Development of intestinal adenomas in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl by 
12 weeks of age. (A) H&E staining shows the formation of high-grade adenomas in the intestinal 
epithelium of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl mice within 12 weeks after Cre induction. 
Pygo2 immunostaining confirms the ablation of Pygo2 in normal intestinal epithelial cells but 
shows Pygo2 expressing cell clusters in adenomatous tissues. Scale bars: 400 µm. (B) Kaplan-
Meier survival analysis was used to determine the cumulative survival of Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/+ and Pygo2fl/fl mice, respectively, after Cre induction. Statistics were 








hyperproliferation of Villin-CreERT2 Catnb  Pygo2 and 
illin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl mice was further evaluated by 
immunohistological staining for deregulation in the expression pattern of Wnt 
 localization of 
al cells (Figure 17A and B)  
al cells whereas 
expression of BCL9-2 is restricted to the differentiated epithelial cells in the villi 
(126). BCL9-2 but not BCL9 was found to be upregulated in early stages of 
intestinal carcinogenesis (adenomas of ApcMin mice and humans) and in human 
colon cancer (126). In order to analyze if the levels of BCL9 proteins were altered 
in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ animals compared to controls, the 
expression of these proteins was analyzed by immunohistochemistry on tissue 
sections. Following activation of Wnt signaling by stabilization of β-catenin an 
upregulation of BCL9-2 was observed neither in the early hyperproliferative 
regions (Figure 17A) nor 34 days after induction (Figure 17B). In parallel no 
major changes in the expression level of BCL9-2 mRNA were detected 18 days 
after induction. At later stages of β-catenin driven intestinal tumorigenesis (after 
34 days) some increase in BCL9-2 mRNA expression was found in one of the 
analyzed Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ intestines  (Figure 18B). 
6.3.3. Characterization of intestinal hyperproliferation and tumors 
induced by stabilized β-catenin 
6.3.3.1. Upregulation and nuclear localization of β-catenin requires Pygo2  
The observed + fl(ex3)/+ fl/+ 
V
signaling components. A slight upregulation of β-catenin was detected in 
intestinal hyperproliferations 18 days after induction with Tamoxifen (Figure 
17A). In contrast, 34 days after induction a clear increase of nuclear and 
cytoplasmic β-catenin was observed. Here, nuclear β-catenin was also found in 
the majority of morphological normal epithelial cells (Figure 17B). Loss of Pygo2 
in the presence of stabilized β-catenin abrogated its nuclear localization. Only the 
hyperplastic areas, which still expressed epithelial Pygo2, showed upregulated 
expression and nuclear β-catenin whereas membranous β-catenin 
staining was seen in morphologically norm
In addition to Pygo2, BCL9 and BCL9-2 are nuclear co-factors of Wnt/β-catenin 
signaling. BCL9 is expressed in all epithelial and mesenchym
 




munohistochemistry with the indicated antibodies on 
sections of the proximal small intestine of control and mutant mice of the indicated genotypes 18 
ays (A) and 34 days (B) after Cre induction. Scale bars: 100 µm.  
 
Figure 17: Upregulation and nuclear localization of β-catenin following deletion of exon 3 in 
hyperplastic intestinal epithelial cells. Im
d
 






and B).  
Figure 18: Intestinal hyperproliferation induced by activated β-catenin do not express 
BCL9-2. (A) Co-immunofluorescence staining of BCL9-2 (red) and BrdU (green) on intestinal 
sections of a tumor and an escaper adenoma from Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ and 
Pygo2fl/fl mice, respectively, 34 days after Tamoxifen induction. Scale bars: 200 µm. (B) qRT-PCR 
analysis on total mRNA isolated from control and mutant mice. The relative expression of BCL9-2 
is shown as % of one control anim ts the mean of at least 3 qRT-PCRs from 
individual mice with the indicated genotypes and their standard error (* p < 0.05).  
 
Interestingly, BCL9-2 positive nuclei were still confined to the differentiated cells 
as confirmed by co-immunofluorescence with antibodies against BrdU and BCL9-
2. This staining revealed no colocalization of proliferative and BCL9-2 expressing 
cells (Figure 18A).  
Moreover, the expression pattern of BCL9-2 was not influenced by additional 
deletion of Pygo2 in this mouse model of intestinal tumorigenesis (Fig
 




In agreement with our previous findings (126) BCL9 expression was also 
unchanged in the intestinal hyperproliferations that arise upon stabilization of β-
catenin (Figure 17A).  
Taken together, these findings demonstrate that stabilization of β-catenin in the 
intestinal epithelium leads to its nuclear accumulation and can be rescued by 
deletion of Pygo2. Furthermore, these early stages of intestinal tumorigenesis do 
not show an upregulation of BCL9-2. 
 
6.3.3.2. Deregulated expression of Wnt/β-catenin target genes and ISC 
marker following stabilization of β-catenin in the intestine 
The effect of mutational activation of β-catenin in the intestine was further 
investigated by expression analyses of Wnt/β-catenin target genes. 
Axin2, a classical Wnt target gene (154), was strongly upregulated in intestinal 
epithelial cells upon stabilization of β-catenin as examined by qRT-PCR analysis 
(Figure 20C). The proto-oncogene c-myc has been identified as a Wnt target gene 
in colorectal cancer cell lines (45). In the normal intestine c-myc is expressed in 
proliferating cells of the crypts (45;46) (Figure 19A and B). In the early 
hyperproliferative intestines of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice the 
expression of c-myc mRNA was on average 5.5 fold upregulated and this 
upregulation further increased 34 days after Cre induction (averaged 7.8 fold) 
(Figure 20C). This was further confirmed by IHC staining which showed an 
increasing number of c-myc positive cells during the development of the intestinal 
pathology. Elevated expression of c-myc was found in the enlarged crypts of the 
hyperproliferative intestines and in almost all cells of the severe 
hyperproliferation that developed after 34 days (Figure 20A and B). 
Moreover the expression of two other Wnt/β-catenin target genes, Sox9 and 
Prox1, both known to be upregulated in intestinal tumors (155;156;163) was 
investigated. qRT PCR and immunohistochemical analysis revealed that both 
ormal intestinal epithelial cells (156) (Figure 20) and 18 days after Cre induction 
genes were strongly upregulated following stabilization of β-catenin on mRNA 
(Figure 19C) as well as on protein level (Figure 20). Prox1 is not expressed in 
n
 




Prox1 was not induced in expanded proliferating crypts (Figure 20A) but rather 
found to be expressed in the hyperplastic epithelium (Figure 20A and B). 
The expression pattern of all three immunohistochemical analyzed Wnt/β-catenin 
target genes correlated with the elevated expression of β-catenin as they were 
expressed in the majority of highly hyperplastic epithelial cells (Figure 20A and 
B) which exhibited a prominent nuclear β-catenin staining (Figure 17A and B). 
As shown by IHC staining the deregulated expression of c-myc, Prox1 and Sox9 
proteins was reversed in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl, but was still 
found in hyperplastic cells and nascent microadenoma that escaped Pygo2 
recombination (Figure 20A and B). Likewise the mRNA expression level of all 
three genes was reduced in double mutant intestines compared to Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice, but was still significantly higher than in 
control mice (Figure 20C). 
Furthermore, the number of Paneth cells, whose differentiation has been 
previously shown to depend on canonical Wnt signaling (60), was increased in the 
hyperproliferative intestines of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice, as 
indicated by IHC staining for Paneth cell marker Lysozyme (Figure 19).  
 
on. Scale bars: 100 µm. Inserts show higher magnifications. 
Figure 19: Mislocalization of Paneth cells following stabilization of β-catenin in the intestinal 
epithelium. Immunohistochemical analysis with an antibody for Lysozyme on intestinal sections 
of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+,Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl and control mice 
34 days after Cre inducti
 
 










Figure 20: Wnt/β-catenin target genes and intestinal stem cell markers are upregulated in a 
Pygo2 dependent manner following stabilization of β-catenin. IHC staining as indicated of 
intestinal sections from Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+,Villin-CreERT2+ Catnbfl(ex3)/+ 
Pygo2fl/fl and control mice 18 days (A) and 34 days (B) after induction with Tamoxifen. Scale 
bars: 100 µm. Inserts show higher magnifications. (C) and (D) qRT-PCR on total mRNA isolated 
from control and mutant mice. The bars show the mean of at least 3 qRT-PCRs from individual 
mice of the indicated genotypes relative to one control animal and their standard error. * marks 
significant changes with a p < 0.05.  
 
The expression of established stem cell markers of the intestine was further 
assessed by qRT-PCR on total mRNA of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ 
nd Pygo2fl/fl intestines, respectively, and compared with control mice. With the 
exception of Bmi1, which marks intestinal stem cells located at the +4 position 





(63), the expression of the intestinal stem cell marker Lgr5, Ascl2 and Msi1 were 
strongly upregulated in Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ intestines and this 
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Figure 21: Perturbation of the EphB receptor system following stabilization of β-catenin in 
the intestinal epithelium. (A) Co-Immunofluorescence staining of BrdU (green) and EphB2, 
EphB3 or EphB4 (red) respectively, on intestinal sections of control und mutant mice. Scale bars: 
100 µm. Inserts show higher magnifications. (B) qRT-PCRs for EphB receptor mRNAs. Shown is 
the relative expression of transcripts as % of one control animal. The bars represent the mean of at 









Since the hyperproliferative epithelium of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ 
intestines represents very early stages of intestinal tumorigenesis these 
transformations were also examined for the expression of EphB receptors by co-
immunofluorescence staining. As shown in Figure 21A intestinal 
hyperproliferations and tumors, indicated by BrdU staining, were strongly 
positive for all three EphB receptors. In contrast, following conditional deletion of 
Pygo2 in these mice their normal expression pattern was restored and only escaper 
adenomas retained elevated EphB receptor expression. The increased expression 
of EphB2, EphB3 and EphB4 following stabilization of β-catenin in intestinal 
pithelial cells and the rescue by Pygo2 deletion was further confirmed by qRT 
PCR analysis (Figure 21B).  
Taken together, these findings demonstrate that stabilization of β-catenin in the 
intestinal epithelium is accompanied by an upregulation of canonical Wnt target 
genes and ISC marker as well as alterations in the EphB receptor system. 
Furthermore, these deregulations apparently depend on the expression of Pygo2.  
 
6.3.3.3. The hyperproliferative intestines induced by mutated β-cateni
are predominantly negative for activated ERK1/2 
 from the cytoplasm to the nucleus (166). In order 
 gain insights into the activation status of this signaling pathway in the intestinal 
e
n 
Mutations in the K-ras oncogene are found in 40–50 % of both colorectal 
adenomas and carcinomas and are supposed to occur at a relatively early stage of 
the carcinogenic process (46;164;165). Upon activation of the Raf-MEK-ERK 
pathway by Ras proteins the mitogen-activated protein kinases ERK1/2 become 
phosphorylated and translocate
to
hyperproliferation of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ mice, sections were 
analyzed immunohistochemical for phosphorylated ERK1/2. As shown in Figure 
22 no phosphorylation of ERK1/2 was detected in the intestinal 
hyperproliferations induced by stabilized β-catenin (d18). In later stages of β-
catenin driven tumorigenesis, 34 days after Cre induction, some scattered 
pERK1/2 positive cells were identified. However, these cells were predominantly 
 




found in normal intestinal epithelial cells located at the border of hyperplastic 
tissues.   
Figure 22: Phosphorylation status of ERK1/2 in intestinal hyperproliferation induced by 
stabilized β-catenin. Immunohistochemical staining for pERK1/2 on intestinal sections of Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+,Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl and control mice 18 and 
34 days after Cre induction. Scale bars: 100 µm. 
 
Thus, immunohistochemical analysis for phosphorylated ERK1/2 did not clearly 
indicate activated Ras signaling in hyperproliferative intestinal cells with elevated 
Wnt/β-catenin activation.  
 
6.4. Pygo2 deletion does not rescue intestinal adenoma 
formation in ApcMin/+ mice 
The role of Pygo2 in intestinal tumorigenesis was further analyzed in ApcMin mice 
(multiple intestinal neoplasia) mice, which have a point mutation in the murine 
homolog of the tumor suppressor gene Apc and develop multiple benign intestinal 
adenomas (89;90). Intestines from Villin-Cre+ ApcMin/+ Pygo2fl/fl mice were 
assessed for tumor number and size at 14 weeks of age. No significant difference 
in the + Min/+ fl/fl  total number of tumors between Villin-Cre  Apc  Pygo2 and control 
ttermates (Villin-Cre+ ApcMin/+ Pygo2fl/+) was observed. Similarly, the 
mall (<2 mm2), middle (2-4 mm2) and large (>4 mm2) small 
as was unchanged after deletion of Pygo2 in 
li
distribution of s
intestinal and colonic adenom
 




pcMin/+ mice. One exception was that Villin-Cre+ ApcMin/+ Pygo2fl/fl mice 
+ /+




atenin (Figure 24A). In contrast to the Catnbfl(ex3) mouse model, loss of epithelial 
Pygo2 did not influence nuclear localization of β-catenin in the context of Apc 
In agreem
A
developed a significantly higher number of small adenomas in the colon (Figure 
23B). The absence of epithelial Pygo2 in adenomas of Villin-Cre  ApcMin  
Pygo2fl/fl was confirmed by IHC (Figure 23A). 
The possibility that Pygo1, which is absent in normal intestinal tissues (126), has 
rescued Pygo2 function in compound mutant mice was ruled out by 
immunostaining, since Pygo1 was not detectable in adenomas of both Villin-Cre+ 
ApcMin/+ Pygo2fl/fl and control mice (Figure 23A). 
Similar to the Catnbfl(ex3) mouse model in ApcMin/+ mice the inactivation of the 
Apc gene by loss of the wild-type Apc allele (LOH, loss of heterozygosity) leads 
to a constitutive activation of the Wnt/β-catenin signalling pathway. In spite of 
this, a parallel Villin-Cre me
least to reduce intestinal tumor development in Apc  mice. 
In order to compare both mouse models the expression of Wnt/β-catenin signaling 
components and target genes was analyzed by immunohistochemical analysis of 
small intestinal adenoma of four-month-old mice. As expected intestinal adenom
of Villin-Cre+ ApcMin/+ Pygo2fl/+ mice exhibited strong nuclear expression of β
c
deficiency (Figure 24B). 
ent with our previous findings (126) expression of BCL9-2 but not 
BCL9 was found to be strongly upregulated in intestinal adenoma of Villin-Cre+ 
ApcMin/+ Pygo2fl/+ mice (Figure 24C and E). This upregulation of BCL9-2 was not 
influenced by Villin-Cre mediated deletion of Pygo2 (Figure 24F). Likewise the 
expression pattern of the Wnt/β-catenin target genes c-Myc, Sox9 and Prox1, 
which were upregulated in intestinal adenomas, did not differ between Villin-Cre+ 
ApcMin/+ Pygo2fl/fl and control mice (Figure 24G-L).  
The phosphorylation status of the MAPK pathway proteins ERK1 and 2 in 
adenomas Villin-Cre+ ApcMin/+ Pygo2fl/+ and Villin-Cre+ ApcMin/+ Pygo2fl/fl mice 
was further addressed. Immunohistochemistry revealed occasional clusters of 
pERK1/2 positive cells in both Pygo2 expressing and Pygo2 deficient adenomas 
and these cells showed also nuclear staining for pERK1/2 (Figure 24M and N).  
 


























Figure 23: Pygo2 deficiency does not alter size and number of adenoma in ApcMin/+ mice.   
(A) IHC analysis of representative adenomas of Villin-Cre+ ApcM Pygo2fl/fl and control mice 
(Villin-Cre+ ApcMin/+ Pygo2fl/+) with the indicated antibodies. Scale bars: 200 µm. (B) Box-Blot 
analysis of the total number and sizes of intestinal adenomas from 3.5 month old Villin-Cre+ 
ApcMin/+  Pygo2fl/fl mice and control littermates. * marks significant differences with a p < 0.05 
(Mann-Whitney-U-Test). 
 
















Figure 24: Immunohistochemical characterization of Apc deficient intestinal adenomas 
from. Representative sections of adenomas from control (A, C, E, G, I, K, M) and Villin-Cre+ 
ApcMin/+ Pygo2fl/fl mice (B, D, F, H, J, L, N) were stained with the indicated antibodies. Scale bars: 
200 µm. 
 
6.5. Concomitant activation of Wnt/β-catenin and K-ras 
signaling in the intestinal epithelium 
We found phosphorylated ERK1/2 in scattered cells of adenomatous tumors 
harboring the ApcMin mutation (Figure 25) but not in intestinal hyperproliferation 
of β-catenin mutant mice (Figure 23). Therefore, we hypothesized that intestinal 
adenomas of ApcMin/+ mice might harbor additional mutations in K-ras and that 
this might be a reason for the failure of Pygo2 deletion to prevent tumor 
development in this mouse model. If so, mutation of K-ras in mice with a 
stabilized β-catenin might resemble the situation in ApcMin/+ mice.  
In order to test this hypothesis and to assess the effect of mutated K-ras on 
intestinal tumorigenesis initiated by mutant β-catenin Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/+/Pygo2fl/fl mice were crossed with conditional K-RasV12 
transgenic animals (137). Expression of the K-rasV12 oncogene is under control 
of a broadly active β-actin promoter and occurs only after Cre-mediated 
recombination (137). 6 weeks after birth compound mutant mice (Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+/ Pygo2fl/fl KrasV12-/ KrasV12+) were treated with 
Tamoxifen for 5 days to induce Cre recombinase activity and the overall survival 
and tumor development was observed. Both Villin-CreERT2+ Catnbfl(ex3)/+ 
Pygo2fl/+ KrasV12- and KrasV12+ mice died at latest 37 days after Cre induction. 
Moreover, Kaplan-Meier analysis revealed no significant difference between the 
survival of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ KrasV12- and KrasV12+ mice, 
respectively (p > 0.05, log-rank test) (Figure 26), indicating that the additional 
mutation of K-ras did not significantly accelerate tumorigenesis. Indeed, the 
histological phenotype of Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ KrasV12+ mice 
did not show any obvious differences to the intestinal hyperproliferation of Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ KrasV12- mice (Figure 27A). 





The successful recombination and therefore activation of the KrasV12 transgene 
was confirmed by PCR analysis using genomic DNA derived from intestinal 
tissues of Villin-CreERT2+ KrasV12- and Villin-CreERT2+ KrasV12+ mice 
(Figure 25). Nevertheless, we did not observe an increased activation of MAPK 
signaling targets pERK1/2 following KrasV12+ activation by 
immunohistochemical staining (data not shown). 
 
Figure 25: PCR for recombination of the conditional transgenic K-rasV12 oncogene. The 
expression of the KrasV12 transgene is under control of a β-actin promoter, but remains silent 
until excision of the GFP-polyA cassette by Cre mediated recombination of the loxP sites (►) 
(137). Successful recombination of the K-rasV12 transgene in intestinal tissues from KrasV12+ 
mice was confirmed by PCR analysis 12 weeks after induction of Villin-CreERT2. Position and 
orientation of the PCR primers used for this analysis are depicted. NTC: no template control. 
 
 
To address the question if the deletion of Pygo2 is still able to rescue intestinal 
hyperproliferation in mice with concomitant β-catenin and K-ras mutations, the 
intestines from Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl KrasV12- mice were 
compared to those from Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl KrasV12+ mice. 




2+ Catnbfl(ex3)/+ Pygo2fl/fl KrasV12- mice several microadenomas were 
etected. Again, these adenomas developed from cells that escaped the 
r Ca  
 
As shown in Figure 28B the intestinal architecture of Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/fl KrasV12+ is considerably normal and similar to Villin-
CreERT
d
recombination of Pygo2 since clusters of dysplastic cells retained Pygo2 
expression (Figure 27B).  
 
Figure 26: Kaplan–Meier survival analysis of mice with simultaneous β-catenin and K-ras 
mutation in the intestinal epithelial cell population. The cumulative survival of Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ KrasV12- and KrasV12+ mice was defined as the time until death 
after Cre induction or the time point the mice were killed due to severe illness. Statistics were 
evaluated by the P log-rank test (p > 0.05).  
 
In conclusion, we were not able to enhance β-catenin mediated tumor formation 
by conditional activation of K-ras. However, experimental evidence for activated 
K-ras signaling in Villin-C eERT2+ tnbfl(ex3)/+ KrasV12+ mice is lacking and 
therefore it remains unclear if deletion of Pygo2 is able to block intestinal tumor 
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magnifications.  
Figure 27: Simultaneous activation of K-ras and β-catenin in the intestinal epithelium. 
Immunohistochemical staining as indicated of (A) Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ and (B) 
Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/fl ice, with ithout act ating mutations in the Kras 
oncogene (KrasV12- and KrasV12+, respectively). Scale bars: 200 µm. Inserts show higher 
 





, that Pygo2 is absolutely required for Wnt driven 
testinal tumorigenesis induced by stabilized β-catenin, deletion of Pygo2 was 
not able to inhibit tumor development following Apc loss. Therefore, the 
influence of reduced Pygo2 protein levels on the proliferation of two colon cancer 
cell lines, that harbor mutations either in the Apc (SW480 (73;79)) or β-catenin 
gene (HCT116 (73;167)) was examined by MTT assay and compared with the 
effects of β-catenin and BCL9-2 knockdown. The MTT assay detects the number 
living cells by measuring intracellular enzyme activity and may therefore reflect 
cell proliferation (168). 
Colon cancer cells were transfected with specific siRNAs against Pygo2, β-
catenin and BCL9-2. The knockdown efficiency was examined on protein level by 
semiquantitative Western blot analysis. As shown in Figure 28B strongly reduced 
levels of all proteins were detected 72 h after treatment with the indicated siRNA. 
Furthermore knockdown of BCL9-2 reduced the expression of Pygo2 protein. 
Unfortunately, no BCL9-2 was detected in 
CT116 cells (Figure 28B).  
t
ficantly inhibited colon cancer cell proliferation by ~ 25 % in SW480 and 70 
 in HCT116 cells, respectively (Figure 28A).  
Interestingly these results show that in contrast to previous published studies 
downregulation of β-catenin had no or only a very slight influence on the 
6.6. The nuclear cofactors of Wnt/β-catenin signaling, Pygo2 
and B 9-2, ar  required for proliferation of colon cancer cells 
We have previously demonstrated increased levels of Pygo2 in colon cancer (126) 
but whether they contribute to tumor growth remains unclear. Although the results 
of this work have shown
in
This is consistent with our previous findings that protein stability of Pygo2 is 
regulated by BCL9-2 (126) since mRNA levels of Pygo2 were not affected by 
BCL9-2 knockdown in this study. 
H
siRNA directed against Pygo2 slightly but significantly decreased the 
proliferation of SW480 and HCT116 cells compared to control siRNA. In SW480 
cells the effect was most prominen  96 h post transfection (~ 40 % reduction), 
whereas in HCT116 cells the proliferation was reduced by half 48 h post 









proliferation of colon cancer cells (Figure 28A) whereas knockdown of both 
Wnt/β-catenin cofactors, Pygo2 and BCL9-2, significantly inhibited their growth. 
Thereby, the effect of Pygo2 was similar in both cells lines, whereas the decrease 
in proliferation after BCL9-2 knockdown was more prominent in HCT116 cells 
which express less BCL9-2 than SW480 cells.  
Taken together, these results implicate the nuclear co-factors Pygo2 and BCL9-2 
in colon cancer cell proliferation. 
Figure 28: Knockdown of Pygo2 and BCL9-2 reduces the proliferation of colon cancer cells. 
(A) Proliferation of SW480 and HCT116 colon cancer cells after knockdown of β-catenin, Pygo2 
or BCL9-2 was examined after 1, 2, 3 and 4 days using MTT assay. Proliferation is expressed as 
fold increase compared with the initial absorbance 24 hours after siRNA treatment. * indicates 
significant differences with p < 0.05. (B) The knockdown of β-catenin, Pygo2 and BCL9-2 was 
confirmed by Western Blot analyses with the respective antibodies. Whole cell protein extracts 72 









































































































eostasis, but is required for intestinal tumor development 
intestinal epithelial cell population (138). 
widely unaffected in adult Pygo2 
7. Discussion 
The role of the Wnt/β-catenin signaling pathway in intestinal homeostasis and 
tumorigenesis is well established (169). During the last decade Pygo2 has 
emerged as nuclear co-factor of β-catenin in canonical Wnt signaling (116), but so 
far its contribution in the regulation of these processes is not fully understood. We 
have recently found that Pygo2 is ubiquitously expressed in the epithelial and 
mesenchymal cells of the intestine. Moreover, it becomes upregulated in intestinal 
adenomas of ApcMin mice and humans as well as in established colorectal cancers 
(126), indicating a role of Pygo2 in these tumors.  
The study presented indicates for the first time that epithelial Pygo2 is dispensable 
for normal intestinal hom
following stabilization of β-catenin. In contrast, we found that loss of Pygo2 failed 
to reduce adenoma formation in the context of Apc deficiency.  
 
7.1. Pygo2 is dispensable for normal homeostasis of the 
intestinal epithelium 
Constitutive Pygo2 deficiency is incompatible with life (119). The consequences 
of loss of Pygo2 in the intestine were therefore studied using conditional Villin-
Cre driven deletion specifically in the 
Consistent with previous reports (118;119) we found the intestinal development of 
Villin-Cre+ Pygo2fl/fl mice at embryonic day 18.5 indistinguishable from control 
mice. The proliferative intervillous region, which is under stringent control of 
Wnt/β-catenin signaling, appeared normal and no changes in β-catenin expression 
levels were observed. However, the intestinal crypts develop in the first weeks 
after birth (77) and  loss of Pygo2 in the adult intestine has not been studied so far. 
Accordingly, while intestinal homeostasis was 
deficient intestines, using BrdU labeling experiments we found a slight decrease 
in proliferation. Thereby the number of proliferating progenitor cells in the 
 




reviously shown in the mammary 
hours after labeling. However, these findings would support a role of Pygo2 as a 
modulator of canonical Wnt signaling regulating the levels of signaling outcome 
rather than to be general necessary for transcriptional activation. 
In agreement with its redundancy in normal intestinal homeostasis, Pygo2 
deletion did not reduce the expression of any of the examined Wnt target genes (c-
myc, Axin2, Sox9, Prox1, EphB2, EphB3, EphB4) including Wnt/β-catenin 
regulated ISC marker (Lgr5, Ascl2, Olfm4). This may rather indicate that the 
number of stem and progenitor cells in Pygo2 deficient intestinal crypts is not 
altered and is consistent with previous findings that the expression of a canonical 
Wnt reporter is unaffected in Pygo2 mutant embryonic intestines (118).  
Taken together, the only anomaly reminiscent of other Wnt pathway mutants 
(46;49;58;170) was the slight reduced epithelial proliferation following ablation 
of Pygo2 in the mouse intestinal epithelium. Overall, our findings argue that 
Pygo2 is dispensable for the normal embryonic development and the Wnt/β-
catenin regulated homeostatic self-renewal of the adult intestinal epithelium. Such 
redundancy of a nuclear cofactor of β-catenin in intestinal homeostasis is not that 
surprising, as it has been previously described for BCL9 and BCL9-2. The 
arkedly regulate any of the examined ISC 
arker that are simultaneously Wnt/β-catenin target genes (Lgr5, Ascl2, Olfm4), 
we found a significantly increased expression of Msi1 after Pygo2 loss. Msi1 is an 
RNA-binding protein involved in posttranscriptional gene regulation by 
specifically binding in the 3´-UTR region of its targets to repress mRNA 
intestinal crypt compartment was comparable to control animals, but BrdU 
incorporation after 48 hours revealed less labeled cells in Villin-Cre+ Pygo2fl/fl 
intestines than in control mice. This could have two explanations. Either the cell 
cycle is decelerated following Pygo2 deletion, presumably due to reduced 
expression of cell cycle genes as it has been p
gland (110). Alternatively there might be a minimal reduced difference in the 
number of progenitor cells in Pygo2 deficient crypts, which was not detectable 2 
simultaneous Villin-CreERT2 mediated deletion of BCL9 and BCL9-2 did not 
affect intestinal homeostasis and Wnt/β-catenin target gene expression in adult 
mice (127). Nevertheless, the BCL9/BCL9-2 proteins have been implicated in 
intestinal tumorigenesis (126;127) (see below). 
Surprisingly, while Pygo2 did not m
m
 




translation (171). Msi-1 expression was observed in both stem cell populations of 
cells located just above the Paneth cells and in CBC cells 
60;172). However, some isolated Msi1 positive cells were also observed higher 
in the crypt and in the transition zone between crypt and villus (173) arguing 
mRNA expression secondary mediated through its target genes. Indeed, in colon 
of Wnt/β-catenin 
plicated in several chromatin remodeling 
events (109-113). Now, in human mammary epithelial cells Pygo2 occupied the 
76). Acetylation of lysine residues of H3 is strongly 
associated with active transcription (177) and therefore reduced levels of H3 
the intestine, the +4 
(1
against Msi1 as a true intestinal stem cell marker. Nevertheless, recent studies 
demonstrated that Msi1 is regulated by the Wnt/β-catenin signaling pathway in 
intestinal epithelial primary cells (174) and human colonocytes (175).  
The molecular mechanisms regulating Msi1 are largely unknown. In the above 
mentioned studies Wnt/β-catenin signaling positively regulated the expression of 
Msi1, while Pygo2 had the opposite effect. Thus, regulation of Msi1 by Pygo2 
might be Wnt/β-catenin independent or Pygo2 may negatively regulate Msi1 
cancer cells we found that Pygo2 has its own set of target genes, which is 
regulated independently of β-catenin ((126) and unpublished data). A very recent 
study could shed light on the underlying mechanism of how Pygo2 regulates the 
expression of Msi1 and other target genes independently 
signaling. Pygo2 has been previously im
promoters of several histone genes and was required for its expression, probably 
by regulating H3K56Ac (1
lysine acetylation in Pygo2 deficient intestinal epithelial cells may contribute to 
the derepression of genes like Msi1 resulting in transcriptional activation. 
However, future work is necessary to elucidate the molecular mechanism of gene 
regulation by Pygo2 in the intestinal epithelium and to identify more genes 
regulated by Pygo2 in the intestine. 
  
7.2. The role of Pygo2 in the context of aberrant Wnt/β-
catenin activation in the intestinal epithelium 
In contrast to the apparent redundancy of Pygo2, BCL9 and BCL9-2, we have 
recently demonstrated that knock-down of these proteins in established colon 
 




th of intestinal 
 reduced the number of cells, but 
the effect was much more prominent in HCT116 cells. Importantly, although 
cancer cells reduced Wnt reporter activity as well as the expression of a subset of 
canonical Wnt target genes (28;126). Furthermore, the BCL9/BCL9-2 proteins 
have been implicated in intestinal tumorigenesis (126;127). Consequently, it is 
conceivable that the nuclear co-factors of the BCL9 and Pygo family may not be 
required for physiological levels of Wnt/β-catenin signaling in the intestinal 
epithelium, but rather contribute to aberrant pathway activation, as it occurs 
during tumorigenesis.  
 
7.2.1. Pygo2 and BCL9-2 might be involved in the grow
tumors 
Proliferation plays a very important role in the carcinogenic process of colon 
cancer and intestinal epithelial proliferation is strongly controlled by the Wnt/β-
catenin signaling pathway (46;94;178-180). Moreover, specifically reducing the 
levels of β-catenin in established colon cancer cell lines has been shown to 
decrease proliferation (181;182). We therefore analyzed the contribution of its 
nuclear cofactors Pygo2 and BCL9-2 in the growth of established human colon 
cancer cells. siRNA mediated gene silencing was used to specifically reduce the 
high levels of Pygo2 in SW480 and HCT116 cells. These cell lines harbor either 
Apc or β-catenin mutations, respectively, leading to constitutive activation of 
Wnt/β-catenin signaling. Using the MTT proliferation assay we were able to show 
that Pygo2 knock-down inhibited the growth of both colon cancer cell lines as 
reflected in their reduced viability. These results are also consistent with previous 
studies where Pygo proteins have been implicated in the growth of glioma, breast 
cancer and ovarian cancer cells (131-134). Furthermore, not only Pygo2 but also 
BCL9-2 was required for the growth of these cells. Thereby, we found that knock-
down of BCL9-2 in both cell lines significantly
BCL9-2 expression in HCT116 cells was not detected in this study, we have 
previously demonstrated lower levels of BCL9-2 in HCT116 than in SW480 cells 
(126). This may result in a more efficient protein knock-down and might explain 
the more prominent effect on the proliferation of these cells.  
 





gs, that BCL9-2 in vivo enhanced intestinal 
adenoma progression (126). 
We found that Pygo2 deletion rescued the phenotypes of stabilized β-catenin in 
The reduced proliferation of SW480 and HCT116 cells after knock-down of 
Pygo2 and BCL9-2 may be related to their demonstrated roles as co-factors in 
Wnt/β-catenin target gene expression (126). 
Surprisingly we were only able to detect a slight but significant decreased growth 
after treatment of SW480 cells with siRNA directed against β-catenin. These 
results are in contrast to the results from Verma et al. who demonstrated reduced 
proliferation after knock-down of β-catenin in SW480 and HCT116 cells likely 
mediated by the observed decrease in the expression of the Wnt/β-catenin target 
genes c-myc and CyclinD1 (151;181;183;184). However, in this study the BrdU 
assay was used to analyze proliferation. Likewise, by the use of vector-based 
RNA interference technique and the MTT proliferation assay Huang et al. have 
shown that downregulation of β-catenin had an inhibitory effect on the 
proliferation of the colon cancer cell line Colo205 (182). 
Our different findings in the analyzed cell lines may be due to the different 
mutation status of SW480 and HCT116 cells. In agreement with our results β-
catenin was required for the maintenance of Apc mutant colorectal tumors (185), 
but its inhibition did not effect β-catenin mutant colon cancer cell growth in vivo 
(186). Similarly, in an earlier in vitro study by Chan et al. the growth or survival 
of HCT116 cells was not influenced by targeted deletion of the mutant allele of β-
catenin (187). 
However, the in vitro results of this study that Pygo2 and BCL9-2 reduced the 
proliferation of human colon cancer cells and the previous demo
upregulation of both proteins in intestinal tumors (126) lead to the assumption that 
they contribute to the growth of intestinal tumors. Furthermore, they are 
consistent with our previous findin
 
7.2.2. β-catenin mediated intestinal tumorigenesis requires Pygo2  
the fetal intestine, including the strong hyperproliferation, indicating that the 
 




T2 is supposed to drive recombination homogenously in 
 (138). Consistent with this increased proliferation was 
found throughout the small intestine upon stabilization of β-catenin. However, the 
g from transformation of the entire epithelium in the proximal 
small intestine to hyperproliferation and nascent microadenoma formation in the 
 
at intestinal tumor 
function of Pygo2 in the intestinal epithelium strongly depends on the levels of 
activated Wnt/β-catenin signaling. 
Therefore, the role of Pygo2 in the context of activated Wnt/β-catenin signaling 
was further examined in the adult intestine. Using a Tamoxifen inducible Villin-
CreERT2 recombinase a mouse model was established, which enabled a 
simultaneous mutation of Pygo2 and β-catenin in the same cells of the adult 
intestine. Villin-CreER
the intestinal epithelium
severity of this hyperproliferation was very irregular in the different parts of the 
intestine, rangin
distal small intestine up to only weak hyperproliferation in the colon.  
While this work was in progress Leedham et al. have published the same
graduated response to β-catenin stabilization and have extensively characterized 
the levels of Wnt/β-catenin pathway activity in the different regions of the gut 
(162). Thereby they found that the sensitivity to Wnt modulation mirrored the 
physiological gradient expression of Wnt/β-catenin target genes (Axin2, Lef1, 
EphB2) and ISC marker (Lgr5, Ascl2 and Olfm4) and a gradually decreasing 
stem-cell number along the anterior-posterior axis. These findings are consistent 
with a previous report demonstrating a gradually decreasing number of Wnt-
activated cells towards the large intestine (188). This gradient may be responsible 
for the inherently variable response to increased Wnt/β-catenin signaling. 
However, by immunohistochemical staining for Pygo2 in Villin-Cre+ Pygo2fl/fl 
mice we found a decreasing gradient of recombination efficiency along the 
anterior-posterior axis, which may contribute to the milder phenotypes observed 
in the distal small intestine and especially in the colon.  
Moreover, considerable number of studies provide evidence that the optimal 
tumorigenic level of canonical Wnt signals varies within the different regions of 
the intestine in sporadic tumors as well as between the colon and small intestine in 
familial adenomatous polyposis (97-99;162;189). Our findings that the intestinal 
phenotype of Villin-CreERT2 mediated stabilization of β-catenin varies along the 
anterior-posterior and the crypt-villus axis support this theory th
 




 top the villi, which exhibit lowest 
levels of Wnt/β-catenin signaling. 
observed phenotypes of 
fl/fl mice. These findings support our hypothesis that 
β-catenin driven intestinal tumorigenesis induced by 
lear β-
catenin in double mutant mice leads to the suggestion that Pygo2 may be involved 
development requires a certain level of Wnt/β-catenin signaling. Although the 
Villin-CreERT2 recombinase is supposed to be active in all epithelial cells no 
transformation was observed in cells at the
As expected, the intestinal hyperproliferation observed upon β-catenin 
stabilization was characterized by an accumulation of nuclear β-catenin and 
increased expression of Wnt/β-catenin target genes, which paralleled the degree of 
hyperproliferation. Furthermore, an upregulation of CBC specific ISC marker and, 
in agreement with their reported role in early stages of intestinal tumorigenesis 
(190), perturbation of the EphB receptor system were found. Supporting our qRT-
PCR results, Leedham et al. demonstrated by in-situ hybridization Lgr5 
expression in dysplastic cells throughout the small intestine, indicating a huge 
expansion of the ISC population (162). Moreover, the 
stabilized β-catenin are consistent with conditional deletion of Apc in the 
intestinal epithelium, including hyperproliferation, increased apoptosis, increased 
Wnt/β-catenin target gene expression and perturbed cell positioning (55;59).  
Taken together, our findings support the CSC hypothesis that mutations convert 
normal stem cells into cells with tumorigenic potential (83;191), as they suggest 
that the mutational activation of β-catenin drives tumor formation only in ISCs.  
In agreement with our findings in the fetal intestine, deletion of Pygo2 in the adult 
intestinal epithelium completely rescued the severe hyperproliferation mediated 
by the stabilization of β-catenin. Moreover, Pygo2 was required for the 
upregulation of the analyzed Wnt/β-catenin target genes and ISC marker. In 
addition, aberrant crypts and nascent microadenomas that gradually developed to 
macroscopic tumors and retained Pygo2 expressing cells appeared in Villin-
CreERT2+ Catnbfl(ex3)/+ Pygo2
Pygo2 is involved in Wnt/
activating mutations of β-catenin. Furthermore, the abrogation of nuc
in nuclear retention of β-catenin in intestinal epithelial cells with aberrant Wnt 
signaling induced by β-catenin stabilization. Thereby, it may be involved in the 
 




roteins (30;192;193).  
 
e+ ApcMin/+ Pygo2fl/fl mice 
upregulation of its target genes and the ISC marker. This would be consistent with 
the initially proposed role of Pygo p
Moreover, our findings in the intestine are consistent with the role of Pygo2 under 
conditions of activated Wnt/β-catenin signaling in another epithelial tissue, the
mammary gland. Here, loss of epithelial Pygo2 completely rescued β-catenin-
induced mammary outgrowth (110). Importantly, the authors for the first time 
provided in vivo evidence for the function of Pygo2 in the regulation of canonical 
Wnt signaling in a mammalian tissue. Thus, Pygo2 not only recruited β-
catenin/BCL9 to target gene promoters but rather promoted Wnt signaling in the 
mammary epithelium through its participation in histone modifications (110). 
These findings from Gu et al. may also apply for the function of Pygo2 in Wnt/β-
catenin signaling in epithelial cells of the intestine. Presumably, the interaction of 
Pygo2 with methylated histone residues and its function in histone gene regulation 
are required to achieve maximal activation of specific Wnt/β-catenin target genes 
in the presence of β-catenin overexpression. 
 
Surprisingly, the results from β-catenin mutant mice were strikingly different to 
our results obtained from conditional deletion of Pygo2 in ApcMin/+ mice. We 
failed to detect any reduction in tumor burden in these mice. In Villin-CreERT2+ 
Catnbfl(ex3)/+ Pygo2fl/fl mice ablation of Pygo2 and mutational activation of β-
catenin is supposed to occur at the same time in the same cells of the intestinal 
epithelium. In contrast, the inactivation of the second allele of Apc in ApcMin/+ 
mice occurs spontaneously by loss of heterozygosity. It could be possible that this 
event occurs in cells that escaped Villin-Cre mediated Pygo2 recombination. 
However, these “escaper cells” were rare and immunohistochemical staining 
revealed that the vast majority of adenomas in Villin-Cr
were negative for Pygo2. We also ruled out the possibility that Pygo1 expression 
was induced in Pygo2 deficient cells to take over its function. Accordingly there 
must be critical differences between both mouse models (see below).  
 
 




rominent nuclear β-catenin staining could be 
identified in transformed cells of both Apc and β-catenin mutant mice. 
rget 
f 
adenomas in Apc mutant mice despite the knock-out of Pygo2 in this mouse 
7.2.3. BCL9-2 might promote tumor progression and adenoma formation 
in Pygo2 deficient mice  
By immunohistochemical analysis p
Accordingly, we did not found differences in the expression of the examined 
Wnt/β-catenin target genes c-myc, Sox9 and Prox1. The ISC marker genes Lgr5, 
Ascl2 and Msi1 have been shown to be upregulated in intestinal adenomas of 
ApcMin/+ mice (159;172;194). Simultaneously, we were able to show increased 
mRNA expression of all three genes following stabilization of β-catenin in 
intestinal epithelial cells. In agreement with the role of EphB receptors in early 
stages of intestinal tumorigenesis (190), we found elevated EphB2/3/4 expression 
in the hyperproliferative intestines from Villin-CreERT2+ Catnbfl(ex3)/+ Pygo2fl/+ 
mice. Similarly, ApcMin/+ adenomas were strongly positive for EphB2 and 3 (195). 
However, in contrast to β-catenin mutant mice we found Pygo2 not being required 
for nuclear β-catenin in intestinal adenomas of ApcMin/+ mice.  In addition, loss of 
Pygo2 failed to decrease the upregulation of the examined Wnt/β-catenin ta
genes in these mice. Importantly, the intestinal hyperproliferation induced by 
stabilized β-catenin did not show an upregulation of BCL9-2 protein as it was 
found in adenomas of ApcMin/+ mice. This might explain the development o
model. Furthermore, this supports our previous finding that BCL9-2 is required 
for early stages of tumor progression (126). We have also reported that BCL9-2 
was more upregulated in ApcMin/+ adenomas than Pygo2 (126). In contrast to 
Legless/BCL9, BCL9-2 contains a nuclear localization signal and does therefore 
not require the interaction with Pygo2 to co-activate Wnt/β-catenin dependent 
transcription (21;126;129).  
The nuclear co-factor BCL9-2 might be sufficient for anchoring β-catenin in the 
nucleus and co-activate Wnt/β-catenin target genes in the context of Apc 
deficiency. Consistent with this we found that knock-down of BCL9-2 in Apc 
mutant colon cancer cells decreased the expression of canonical Wnt targets like 
c-myc, Axin2, EphB2 (126). The upregulation of BCL9-2 in ApcMin/+ adenomas 
may further contribute to an increased malignancy, as overexpression of BCL9-2 
 




ock-out of BCL9 and 
 
 aberrations (translocations or other 
ents) (196-198). Loss of Apc function has been shown to be associated 
al instability (199;200). BCL9, the homologue of BCL9-2, is 
 mice a nonsense mutation at codon 850 in Apc leads to a truncated 
protein with loss of all β-catenin binding repeats (79;90), raising the assumption 
that the levels of aberrant Wnt/β-catenin signaling are similar high to those 
in vivo promoted adenoma formation and induced invasion of adenomas in 
compound ApcMin/+; K19-BCL9-2 mice (126). The Kn
BCL9-2 in mice failed to prevent the formation of chemically induced colon 
tumors but lead to reduced tumor size (127). Moreover, the intestinal tumors from 
BCL9/BCL9-2 double knock-out mice showed reduced expression of genes
associated with EMT, tumor invasion and metastasis (127).  
Overall, these findings indicate that BCL9-2 promotes intestinal tumor 
progression, while Pygo2 may be required for tumor initiation. The upregulation 
of BCL9-2 in Apc mutant cells may prevent that loss of Pygo2 inhibits tumor 
development. However, future studies are required to further support this 
hypothesis.  
BCL9-2 itself is not a target of Wnt/β-catenin signaling (126) and so far, the 
mechanism of the upregulation of BCL9-2 is unknown. Colorectal tumors 
characteristically display chromosomal instability with both aneuploidy (changes 
in chromosome number) and chromosome
rearrangem
with chromosom
translocated in B-cell malignancies (201). Therefore, it might be possible that 
rearrangements of the BCL9-2 gene locus leading to its overexpression are linked 
to the chromosomal instability in Apc mutant cells (126). So far, alterations on 
chromosome 11q22 that harbors the BCL9-2 locus were found in 64 % of colon 
cancers (202). Further investigations, e.g. using fluorescence in situ hybridization 
techniques, are needed to examine potential translocations or gene duplications of 
BCL9-2 in Apc versus β-catenin mutant colon cancers.  
 
7.2.4. Wnt/β-catenin independent functions of Apc and different 








PCR data indicate that adenomas of ApcMin/+ 
mice exhibit much higher levels of Wnt/β-catenin signaling than the 
induced by an N-terminal truncated β-catenin that escapes degradation. However, 
our preliminary unpublished qRT-
hyperproliferative intestines of β-catenin mutant mice. Similarly, we found much 
higher Wnt reporter activity in colon cancer cells with Apc mutation (SW480) 
than in β-catenin mutant HCT116 cells (126). Different levels of Wnt/β-catenin 
signaling were also reported in Apc mouse models with different mutations 
(194;203) and according to the ‘just right’ model variable levels of Wnt/β-catenin 
pathway activation differential influence tumor susceptibility (189;203;204). This 
might further explain why deletion of Pygo2 alone is not sufficient to reduce the 
high levels of Wnt/β-catenin signaling ApcMin/+ adenomas. Probably additional co-
factors including BCL9-2 cooperate in this context to further increase canonical 
Wnt signaling. Supporting this, Pygo2 was only required for the regulation of a 
subset of Wnt/β-catenin target genes in SW480 colon cancer cells (126). 
Apc and β-catenin mutations are not functionally equivalent. Whereas β-catenin 
purely drives canonical Wnt signaling, Apc has additional Wnt independent 
functions, e.g. its contribution in the regulation of mitosis and apoptosis (199;205-
207). The truncated Apc protein in ApcMin/+ mice contains an intact Armadillo 
repeat domain (90). This Armadillo repeat domain is involved in protein-protein 
interactions with Asef, a GTP-exchange factor for Rho and Rac (208;209), the 
regulatory subunit B56 of protein phosphatase 2A (PP2A) (210) and the kinesin 
superfamily-associated protein 3 (Kap3) (211). Furthermore, the Armadillo 
repeats are implicated in intestinal tumorigenesis (212). Recently, Asef and Asef2 
have been shown to be required for adenoma formation in ApcMin/+ mice (213).  
Such β-catenin independent Apc functions may contribute to the inability of 
Pygo2 in reducing adenoma development in ApcMin/+ mice, as they are likely to 
influence the degree of dependency on Wnt/β-catenin pathway activation in 
intestinal tumors.  
 
 




Catnb  mice 
 (217-219). We therefore wondered whether mutation of the K-ras 
Min/+
mutant mice was slightly 
decreased compared to β-catenin mutant mice and probably a larger cohort needs 
 be analyzed to obtain significant differences. Moreover, we were not able to 
tion is not a potent biomarker for elevated Ras-
signaling, since the K-ras mutation status did not always correlate with ERK1/2 
7.2.5. Intestinal adenomas of ApcMin/+ mice may harbor additional 
mutations in oncogenes and/or tumor suppressor genes 
Additional mutations in other oncogenes and/or tumor suppressor genes in 
intestinal adenomas from ApcMin/+ mice as they are found in established colorectal 
cancers may further explain the difference to Villin-CreERT2+ fl(ex3)/+
regarding loss of Pygo2. Along with large-scale genomic changes and epigenetic 
alterations mutations in K-ras, B-raf, Smad 2 & 4, PI3k, Msh2, Mlh1, p53 have 
been observed during colorectal cancer progression (72;78;214-216). 
Furthermore, several studies reported that K-ras enhanced Apc tumor 
development
gene occurred in Apc  adenomas. By immunohistochemistry we identified 
clusters of pERK1/2 positive cells in intestinal adenomas of ApcMin/+ mice. In 
contrast phosphorylation of ERK1/2 was not observed in the majority of the early 
hyperproliferations that developed upon stabilization of β-catenin in the intestinal 
epithelium. We therefore tried to additionally mutate K-ras in intestinal epithelial 
cells with stabilized β-catenin and intercrossed conditional K-rasV12 mice, which 
harbor a glycine to valine substitution at codon 12 (137). This mutation affects the 
GTPase activity of K-ras and locks the protein in its active, GTP-bound state, 
leading to constitutive signaling to downstream targets (220-222). These kind of 
K-ras mutations were often found in colorectal adenocarcinomas (165;223;224). 
Although PCR analysis confirmed the successful K-rasV12 transgene 
recombination, it did not markedly accelerate β-catenin mediated tumorigenesis. 
The overall survival of compound β-catenin and K-ras 
to
detect increased levels of phosphorylated ERK1/2 in K-ras mutant mice. This 
does not necessary implicate inactivity of the K-ras transgene. Several studies 
suggest that ERK1/2 activa
phosphorylation (218;225-227). Moreover, in addition to its function in activating 
Raf/MEK/ERK signaling K-ras has been shown to interact with multiple 
downstream effectors with demonstrated roles in Ras-mediated oncogenesis 
 





methylation of either H3-K4 or H3-K27 residues are frequently overexpressed in 
C2 (h
(228). However, loss of Pygo2 was still able to prevent tumor development in 
mice with concomitant mutation of β-catenin and K-ras, but it remains unclear if 
the introduced oncogenic K-ras transgene was functionally active.  
Taken together, our results do not rule out K-ras mutations in intestinal adenomas 
ApcMin/+ mice, but to clearly answer this question, the mutational status of the K-
ras gene needs to be analyzed in both ApcMin/+ and Villin-CreERT2+ Catnbfl(ex3)/+ 
mice. 
 
7.2.6. Epigenetic alterations may be responsible for the context 
dependent function of Pygo2 in intestinal tumorigenesis 
The transcription of Wnt/β-catenin regulated genes is controlled by trimethylation 
of H3K4 (229;230) and key histone methyltransferases, that cata
neoplasia (231). An increasing number of studies have implicated Pygo proteins 
in chromatin remodeling (109-113) and recently in the mammary gland this 
function of Pygo2 was linked to the regulation of Wnt/β-catenin signaling in vivo 
(110). The authors showed that the regulation of mammary cell proliferation 
required not only interaction of Pygo2 with BCL9-β-catenin complexes, but rather 
its ability to interact with H3K4me3 at Wnt/β-catenin target genes. Pygo2 might 
exhibit similar functions in the context of aberrant Wnt/β-catenin signaling in the 
intestinal epithelium. Alterations in epigenetic modifications or mutations in 
histones or histone modifying enzymes may be responsible for Pygo2 independent 
tumor development in ApcMin/+ mice. Indeed, there is experimental evidence for 
deregulations in histone modifying enzymes including histone acetyltransferases 
(HATs) and methyltransferases (HMTs) in colon cancer (232). Somatic mutations 
in the HAT p300 were identified in gastric and colorectal cancers (233-235) and 
mutations in HDA istone deacetylase) in sporadic colorectal cancers with 
icrosatellite instability (236). The HMT MLL3 was frequently mutated in colon 
cancer cells and primary colon tumors (237). Furthermore, elevated levels of 
MLL2, which contains a SET domain specifically implicated in H3K4 
methylation, were found in human colon and breast cancer and in colon cancer 
m
 




es CBP and 
p300 are targets for chromosomal translocations associated with human leukemias 
canonical Wnt signaling, occurred normally in the absence of Pygo2 (119). 
cell lines, e.g. in SW480 cells which harbor Apc mutations (238). Interestingly, 
the MLL2 homologue MLL as well as the histone acetyltransferas
(239-242) and chromosomal translocations are also a frequent event in many 
colon tumors (196-198).  
Pygo2 associated with MLL2 in human breast cancer cells (113) and with CBP in 
Apc mutant SW480 colon cancer cells (111). Therefore one may speculate that 
potential alterations in these genes or so far unidentified interaction partners of 
Pygo2 in Apc mutant intestinal tumors may interfere with the described function 
of Pygo2 in promoting trimethylation of H3K4 and acetylation of H3K9/K14 and 
in the regulation of histone gene expression (110-113;176). 
However, future studies are necessary to clearly identify the molecular mechanism 
of how Pygo2 regulates gene expression in intestinal epithelial cells with aberrant 
activation of the canonical Wnt signaling pathway and thereby is involved in 
intestinal tumorigenesis.  
 
7.3. The function of Pygo2 in mammalian tissues is context 
dependent 
The results of this work, that Pygo2 is apparently functional redundant for Wnt/β-
catenin signaling in the normal intestinal epithelium and was required for aberrant 
pathway activation mediated by stabilized β-catenin but not by loss of Apc, 
support its previously demonstrated context dependency.  
Although constitutive deletion of Pygo2 is embryonic lethal, genetic studies in 
mice revealed that the nearly exclusive role of Pygo in Drosophila Wg/Wnt signal 
transduction is not true for mammalian tissues. Typical Wnt phenotypes like the 
early developmental defects observed in β-catenin, Wnt3a or Tcf1/Lef1 deficient 
mice (243-245) were not observed in Pygo2 null mice. Rather Pygo2 has been 
shown to act context dependent and its involvement in various Wnt/β-catenin 
dependent developmental processes varies from step to step. Accordingly, in the 
developing kidney Pygo2 was required for ureteric bud morphogenesis and Wnt 
reporter gene expression while nephron induction, which also depends on 
 





 was not only 
more, our results support the proposed role of Pygo2 as a modulator of 
ent with previous analysis of Wnt reporter and 
target gene expression in mammalian tissues (110;118;119;121) we showed that 
monstrated 
that Pygo2 does not regulate normal levels of Wnt/β-catenin signaling in the 
Similarly Pygo2 was involved in mammary gland morphogenesis but not required 
for Wnt/β-catenin dependent mammary fate induction (110). In contrast to our 
findings in the intestinal epithelium, in the mammary gland  Pygo2
required for stabilized β-catenin induced mammary outgrowth but also for the 
regulation of normal stem cell proliferation and physiological levels of Wnt/β-
catenin target gene expression (110).  
Further
canonical Wnt signaling. In agreem
knockdown of Pygo2 reduced but did not completely abolished canonical Wnt 
signaling in human colon cancer cells (126). Moreover, this work de
intestinal epithelium but rather is required for aberrant pathway activation. 
There were also reported Wnt/β-catenin independent functions of Pygo2 during 
lens development and spermatogenesis (112;120) and were further supported by 
the findings from Gu et al. that Pygo2 also facilitated histone H3 trimethylation in 
bulk chromatin and regulates histone gene expression (110;176). We have also 
demonstrated a Wnt/β-catenin independent regulation of EphB3/B4 and ephrin-
B1/B2/B3 expression by Pygo2 in human colon cancer cells (126).  
However, the results from this study argue for a role of Pygo2 in Wnt/β-catenin 
signaling in the intestinal epithelium, but do not rule out, that it may also have β-
catenin independent functions. 
Taken together, our data may suggest Pygo2 as a potential therapeutic target to 








signaling cascades the Wnt/β-catenin signaling pathway 
bryonic development as well as adult tissue 
ologues, is 
his study shows for the first time, that Pygo2 is dispensable for the normal 
elial cells did not affect the normal embryonic development or the 
scued the increased 
8. Summary 
 
In cooperation with other 
is an essential regulator of em
homeostasis and stem cell proliferation. Mutations in components of this signal 
transduction pathway, which lead to aberrant activation of β-catenin, are 
frequently observed in human cancers including colon cancer and other 
degenerative diseases. Pygopus proteins have emerged as nuclear co-factors of β-
catenin and are supposed to act in a context dependent way by modulating 
canonical Wnt signaling. Pygo2, one of the mammalian Pygopus hom
involved in neoplastic transformation of multiple cell types. Although 
overexpressed in colon cancer its role in intestinal tumorigenesis is not yet 
investigated.  
T
intestinal homeostasis, but is essential for intestinal tumor development induced 
by mutant β-catenin. Conditional Villin-Cre mediated deletion of Pygo2 in mouse 
intestinal epith
homeostasis of adult intestine. Moreover, loss of Pygo2 did not influence the 
expression of Wnt/β-catenin target genes. However, Pygo2 deficiency in the 
context of aberrant Wnt signaling mediated by stabilization of β-catenin 
completely blocked intestinal hyperproliferation and re
expression of Wnt/β-catenin target genes and of intestinal stem cell marker. 
Surprisingly, when deleted in ApcMin/+ mice Pygo2 failed to prevent or even 
reduce tumor development.  
Comparing both mouse models we found upregulation of BCL9-2 in intestinal 
adenomas of ApcMin/+ mice but not in the hyperproliferation of β-catenin mutant 
mice, which suggests that BCL9-2 might be sufficient to promote tumor 
progression in the context of Apc deficiency. We further demonstrated that both 
Pygo2 and BCL9-2 were required for the proliferation of human colon cancer 
cells in vitro.  
 





In addition, we found phosphorylation of ERK1/2, a downstream effector of K-
ras, in intestinal adenomas of ApcMin/+ mice but not in the early hyperproliferation 
of β-catenin mutant mice, indicating that Apc deficient tumors acquired additional 
mutations. 
 
Taken together, our data suggest that the function of Pygo2 in the intestine is 
context dependent. Pygo2 appears to be redundant for the normal intestinal 
epithelium, but may be required for tumor initiation induced by aberrant Wnt/β-
catenin signaling. Therefore, Pygo2 might be an attractive therapeutic target in 
early intestinal tumors that arise upon mutation of β-catenin. 
 





Zelltypen mit anschließender Ausbildung von Tumoren beteiligt. 
r physiologischen Bedingungen scheint Pygo2 
9. Zusammen
 
Der Wnt/β-catenin Signalweg reguliert zusammen mit anderen Signalkaskaden 
die Embryogenese sowie auch die Homöostase und die Proliferation der 
Stammzellen im adulten Organismus. Mutationen in Komponenten dieses 
Signaltransduktionsweges führen zu einer aberranten Aktivierung von β-catenin 
und wurden in vielen verschieden Krebsarten einschließlich Darmkrebs 
beobachtet. Die transkriptionelle Akivität von β-catenin wird von verschiedenen 
nukleären Kofaktoren beeinflusst. Hierzu zählen insbesondere die Proteine der 
Pygopus Familie, die in Drosophila eine essentielle Rolle im kanonischen Wnt-
Signalweg spielen, in Vertebraten allerdings vielmehr Kontext abhängig agieren. 
Insbesondere Pygo2 ist hierbei vermutlich auch an der malignen Transformation 
verschiedener 
Auch wenn bereits gezeigt werden konnte, dass Pygo2 in Darmtumoren 
überexprimiert wird, ist bisher unbekannt, ob es tatsächlich eine Rolle bei der 
Entstehung von intestinalen Tumoren spielt.  
Anhand von genetischen Experimenten in der Maus zeigt diese Arbeit zum ersten 
Mal in vivo, dass Pygo2 für die normale Homöostase des Darms nicht essentiell 
ist, aber an der Ausbildung von Darmtumoren, welche durch eine Stabilisierung 
von β-catenin induziert werden, beteiligt ist. Weder im embryonalen noch im 
adulten Darm beeinflusste der konditionale Villin-Cre bedingte Knock-out von 
Pygo2 in epithelialen Zellen die normale embryonale Entwicklung oder die 
Homöostase im adulten Darm. Auch für die Regulation von Zielgenen des Wnt/β-
catenin Signalweges unte
funktionell redundant zu sein. Im Gegensatz dazu verhinderte der Verlust von 
Pygo2 die Entstehung von β-catenin induzierten intestinalen Tumoren und 
normalisierte die damit verbundene Hyperproliferation sowie die erhöhte 
Expression von Wnt/β-catenin Zielgenen und intestinalen Stammzellmarkern. 
Überraschenderweise konnte die Ausbildungen von Adenomen in ApcMin/+ 
Mäusen durch Deletion von Pygo2 nicht verhindert werden.  
 





pithelialen Zellen BCL9-2 für die Tumorprogression verantwortlich 
eiterhin konnte gezeigt werden, dass sowohl der knock-down von Pygo2 als 
auch von BCL9-2 in human Kolonkarzinomzellen die Proliferation reduzierte.  
Zusammenfassend weisen die Ergebnisse dieser Arbeit daraufhin, dass die 
unktion von Pygo2 im Darm Kontext abhängig ist. Während in normalen 
epithelialen Zellen des Darms Pygo2 offensichtlich funktionell redundant ist, 
scheint es für die Ausbildung von intestinalen Tumoren, welche durch 
dereguliertes Wnt/β-catenin induziert werden, essentiell zu sein. Daher könnte 
Pygo2 ein idealer Angriffspunkt für die zielgerichtete Therapie von Darmtumoren 
mit β-catenin Mutation sein.  
 
Der Vergleich beider Mausmodelle ergab eine erhöhte Expression von BCL9-2 in 
den Adenomen der ApcMin/+ Mäuse aber nicht in den Hyperplasien, die durch 
aktiviertes β-catenin induziert wurden. Dies könnte darauf hinweisen, dass in Apc 
mutierten e
ist. W
Anhand von immunohistochemischen Analysen des Phosphorylierungsstatus von 
ERK1/2, einem „downstream“ Effektor von K-ras, konnten außerdem pERK1/2 
positive Zellen in den intestinalen Adenomen von ApcMin/+ Mäusen, nicht aber in 
hyperproliferierenden Zellen mit stabilisierten β-catenin nachgewiesen werden.  
F
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